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Abstract: 
Immune pressure exerted by host factors including MHC class I-mediated cytotoxic T 
cell control affects HIV disease progression and drives the development of viral escape 
mutations; nonetheless, the relationship between host immunity and HIV central nervous 
system (CNS) disease remains poorly understood. The simian immunodeficiency virus 
(SIV) macaque model recapitulates key features of HIV infection including development 
of AIDS and CNS disease. To investigate host factors regulating SIV CNS disease 
progression, we compared the incidence of SIV encephalitis and the effects of MHC class 
I allele expression on the development of CNS disease in pigtailed macaques versus 
rhesus macaques. Species-specific differences in susceptibility to SIV disease 
demonstrated that host factors are critical to SIV CNS disease progression. We extended 
these studies by examining CNS pathogenesis in pigtailed macaques expressing the 
MHC-I allele Mane-A1*084:01:01, which confers resistance to SIV-induced CNS 
disease in pigtailed macaques and induces viral development of prototypic escape 
(K165R) in the immunodominant SIV Gag KP9 epitope. Insertion of the Gag K165R 
escape mutation into molecularly cloned SIV/17E-Fr resulted in reduced viral replication 
compared to wildtype SIV/17E-Fr in vitro. To investigate viral fitness in vivo, we 
inoculated six Mane-A1*084:01:01 expressing macaques: three with SIV/17E-Fr K165R, 
and three with wildtype, parental SIV/17E-Fr. We found lower CSF, but not plasma, viral 
loads in animals inoculated with SIV/17E-Fr K165R versus those inoculated with 
wildtype, and although the escape mutation K165R was genotypically stable in the 
plasma, it rapidly reverted to wildtype Gag KP9 in both CSF and in microglia. To induce 
Gag KP9-specific CTL immune pressure, we vaccinated two Mane-A*084:01:01 
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expressing pigtailed macaques with Gag KP9 peptide loaded onto a virus-like particle 
(VLP) vaccine. Both animals developed robust KP9-specific tetramer responses to 
vaccination, and upon challenge with SIV/17E-Fr, developed lower viral replication in 
the CSF but not the plasma. These data clearly demonstrate that viral fitness in the CNS 
is distinct from the periphery. As therapeutic vaccination strategies to enhance CTL 
responses against HIV Gag could promote HIV escape, it is vital that we understand the 
consequences of viral escape on CNS disease. 
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HIV Background 
 Over three decades ago, a new immunosuppressive syndrome decimated 
communities of young men nationwide. Patients were succumbing to a spectrum of 
diseases unusual in this population of young, otherwise seemingly healthy individuals. 
These included cryptococcal meningitis, tuberculosis, toxoplasmosis, and neoplasia 
including lymphoma and Kaposi’s sarcoma. As the only common link amongst these 
initial cases was a history of homosexual activity, sexual transmission was suspected.  
Shortly thereafter, the causative agent was discovered to be the human 
immunodeficiency virus (HIV), an RNA virus in the family Retroviridae (genus 
Lentivirus). The immunosuppressive syndrome, characterized by plummeting CD4+ T 
cell counts, was termed Acquired Immunodeficiency Syndrome (AIDS). Since the 1980s, 
the virus has spread worldwide, affecting people regardless of sexual orientation, race, or 
socioeconomic status. Worldwide, over 36 million people have died as the result of HIV 
infection (WHO fact sheet, http://www.who.int/), and HIV/AIDS continues to be an 
important public health issue today. In 2012, an estimated 35.3 million people worldwide 
were living with HIV infection (WHO). In the United States alone, approximately 50,000 
people are newly infected every year (CDC 2010 survey, www.cdc.gov). Of particular 
concern to Johns Hopkins Hospital, Maryland has the third highest rate of HIV diagnosis 
of states/territories in the nation, with Baltimore-Towson ranking as the sixth highest 
diagnosis rate of any major metropolitan area (http://phpa.dhmh.maryland.gov/). As of 
2011 (the last survey done), Maryland has approximately 27,710 individuals living with 
HIV and/or AIDS (http://phpa.dhmh.maryland.gov/).  
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Viral structure and genes 
HIV is a roughly spherical virion roughly 120 nm in diameter containing two 
copies of the positive sense RNA genome within a protein capsid surrounded by a lipid 
bilayer envelope. It is classified in the family Retroviridae due to its unique use of 
reverse transcription for viral replication in a host cell. In particular, HIV is further 
classified as a Lentivirus (taken from lente, [Latin for slow]). Lentiviruses are unique 
amongst retroviruses, not only because of the characteristic protracted course of disease 
often seen in hosts, but also because the genome encodes for several accessory and 
regulatory proteins. In addition, lentiviruses are able to infect and replicate in some types 
of non-dividing cells.[1] Besides HIV in humans, this genus includes viruses that affect 
multiple species, including feline immunodeficiency virus (FIV), equine infectious 
anemia virus, caprine arthritis encephalitis virus (CAEV), visna/maedi virus, and simian 
immunodeficiency virus (SIV). In humans there are two main subtypes of HIV: HIV-1, 
which is most closely related to viruses found in West African chimpanzees and gorillas, 
and HIV-2, which is related to viruses found in another African primate, the sooty 
mangabey. HIV-1 is the more common and more pathogenic of the two subtypes, and it 
is the most common subtype seen in the United States.  
As with other retroviruses, the majority of the HIV-1 genome encodes for the 
structural genes gag (group-specific antigen), pol (polymerase), and env (envelope 
glycoproteins). In addition, HIV-1 contains six accessory/regulatory genes: vif, vpr, vpu, 
rev, nef, and tat. Tat and Rev are gene regulatory proteins necessary for successful 
transcription and RNA export from the nucleus.[1, 2] The rest are accessory proteins that 
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alter host cell surface marker expression, affect viral infectivity, and aid in viral 
nucleoprotein transport.  
In total, the HIV-1 genome has 9 open reading frames, and the mature virion is 
comprised of 15 proteins and the diploid viral genome. The gag gene is translated into a 
precursor polyprotein that is then cleaved by viral protease into: matrix (MA), capsid 
(CA), nucleocapsid (NC), and p6. CA forms the conical core of the virus that surrounds 
the genomic RNA, NC, enzymes, and accessory proteins. MA is integral in virion 
assembly, serving both to target Gag and Gag-Pol precursor proteins to the cell 
membrane as well as incorporating Env glycoproteins into the viral particles. NC serves 
to bind the genomic RNA and deliver it to the developing virion. The final component of 
the polyprotein Gag is p6, which incorporates the accessory protein Vpr during virion 
assembly and helps mediate efficient virion release from the cell membrane.  
The pol gene encodes for three Pol protein products: protease (PR), reverse 
transcriptase (RT), and integrase (IN). The virion that buds from an infected cell is 
immature, containing Gag-Pol polyprotein precursors. Larger precursor proteins must be 
cleaved by PR into their protein components (MA, CA, NC, PR, RT, and IN) before the 
virion fully matures to an infectious form. RT, the enzyme that is a feature of all 
retroviruses, contains both RNA-dependent and DNA-dependent DNA polymerase 
functionalities. Following the creation of double stranded viral genomic DNA by RT, IN 
is responsible for integration of this viral DNA into the host chromosome.  
The env gene encodes the precursor protein gp160, which is cleaved by a cellular 
protease into gp120/surface (SU) and gp41/transmembrane (TM) domains. Together, 
gp120 and gp41 form the glycoprotein spicules on the virion envelope that is responsible 
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for cellular receptor/coreceptor interactions as well as membrane fusion, with gp41 
anchoring the complex within the virion envelope.  
 
Viral Life Cycle 
The life cycle of HIV-1 is one of the most complex of viruses, with extensive 
exploitation of existing cellular machinery.[1, 3] Over the last three decades, this life 
cycle has been studied considerably, and although we still lack a comprehensive 
understanding of all of the nuances, an understanding of this life cycle has illuminated 
many potential targets for pharmaceutical intervention. 
Cell entry and viral uncoating 
The life cycle of HIV-1 starts with entry into the host cell by fusion mediated by 
trimers of the Env proteins gp120 and gp41. Host cell CD4+ receptors and coreceptors 
such as CCR5 and CXCR4 are recognized by gp120. This binding prompts a 
conformational change in gp41, which subsequently reveals the domain that mediates 
fusion of the viral envelope with the cell membrane. After cell entry, the virus undergoes 
uncoating, in which the remaining viral components transition to the reverse transcriptase 
complex and the capsid is lost.[3] 
Reverse transcription and the pre-integration complex 
Mediated by RT, reverse transcription is the process in which HIV-1, like other 
members of the family Retroviridae, converts the single stranded RNA genome into 
double stranded proviral DNA. The process is initiated by cellular tRNA, which binds to 
the primer binding site (PBR) in the HIV genome, priming the generation of a 
DNA/RNA hybrid. An RNaseH domain on RT then digests away the RNA portion of this 
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hybrid, leaving a minus strand short segment of DNA known as the minus-strand strong 
stop DNA. The minus-strand strong stop DNA performs first strand transfer by jumping 
from the 5’ to the 3’ end of the viral RNA, and the newly synthesized DNA strands 
hybridizes to the complementary long terminal repeat (LTR) region on the RNA priming 
minus-strand DNA synthesis. The original viral RNA is partially digested away by 
RNaseH, leaving fragments of viral RNA that are then used to prime plus strand DNA 
synthesis at the central polypurine tract (PPT). After the cellular tRNA is degraded by 
RNaseH, plus-strand synthesis is completed with two termination sites: one at the end of 
the minus-strand and the other at the central termination sequence (CTS), leaving a 
central “flap” of DNA that is important for the next step--transport of the DNA into the 
nucleus. Second strand transfer occurs when the PBS on the minus-strand hybridizes with 
the PBS on the plus-strand, allowing elongation to continue.  
Once reverse transcription is complete, the newly made double stranded viral 
DNA is associated with RT, IN, MA, Vpr, and DNA-binding protein in the pre-
integration complex (PIC). The size of the highly compacted PIC is believed to be 
approximately 28nm.[3] The PIC is transported to the nucleus in a process that is 
incompletely understood, but is believed to involve Vpr, IN, MA, and the aforementioned 
DNA “flap”.[1, 3] 
Integration and Recombination 
Once in the nucleus, IN cleaves two bases from the 3’ end of both strands of the 
linear viral DNA, creating a “sticky end”. IN makes the same cleavage in chromosomal 
DNA, and the ends are joined with the aid of cellular DNA repair enzymes. In order for a 
replication competent virus to be produced, the viral genome must be successfully 
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integrated into the host DNA. The integrated viral genome may be either latent or 
transcriptionally active, which is partially determined by the location of integration in the 
host genome. There are also three other possibilities, none of which result in a replication 
competent virus: 1) the ends of the viral DNA may join to form a 2-long terminal repeat 
(LTR) circle, 2) homologous recombination may result in a 1-LTR circle, or 3) the viral 
DNA may recombine to form a rearranged circle.  
Gene expression and RNA transport  
The viral LTR contains promoter elements, the initiator, TATA-box, and sites to 
help position RNA polymerase II so that transcription is initiated; however, efficient 
elongation cannot occur without the action of the viral protein Tat. The transcriptional 
transactivator viral protein Tat greatly increases the rate of viral transcription by binding 
the transactivation response region (TAR) at the 5’ end of the viral genome and recruiting 
host positive transcriptional elongation factor b (P-TEFb). HIV transcription produces 
multiple complex transcripts, some of which contain introns and cannot exit the nucleus 
by normal host pathways. Whereas the intronless multiply spliced transcripts can exit the 
nucleus via normal export pathways, the HIV protein Rev is responsible for transporting 
intron-containing unspliced and partially spliced viral RNA from the nucleus by binding 
the Rev-responsive element (RRE) in the env sequence, allowing host nuclear export 
machinery to bind. 
Virion assembly, budding, and maturation 
Once viral proteins have been synthesized, determinants in the Gag precursor 
protein Pr55Gag are responsible for localization at the plasma membrane via the MA 
domain, genomic encapsidation via the NC domain, association with Env glycoproteins 
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via MA, and stimulation of budding via p6. Maturation of the virus particle occurs after 
budding when viral PR cleaves Gag and GagPol precursor proteins to generate the 
progeny proteins.  
 
Clinical Features and Management of HIV-1/AIDS 
We now know that HIV-1 is transmitted through the exchange of bodily fluids, 
such as blood, semen, vaginal secretions, and milk. Within the US, the most common 
forms of transmission are unprotected sex and sharing needles during intravenous drug 
use (www.cdc.gov). The risk of transmission is dependent on a number of factors, one of 
the most important of which is plasma viral load; if the viral load is less than 400 
copies/µL, either due to successful antiretroviral treatment or immunologic control, there 
is a very low risk of transmission to another individual.[4-6] Other infectious genital 
infectious diseases, such as Herpes simplex-2 (HSV-2) viral infection[7, 8] and bacterial 
vaginosis[9] have been associated with an increased risk of HIV acquisition. Conversely, 
medical male circumcision has been shown to reduce the risk of heterosexual acquisition 
of HIV.[10] 
Clinical signs begin approximately 2-4 weeks after HIV-1 infection. Typically 
these consist of “flu-like” or “mononucleosis-like” symptoms, consisting of fever, body 
aches, lymphadenopathy, sore throat, rash, and headache. Because of the similarity of 
these symptoms to flu, most individuals do not immediately seek medical care. This stage 
is termed primary HIV infection. Shortly after infection there is a brief period of rapid 
viral replication with peak viremia occurring approximately two weeks post infection.[11, 
12] Immediately following this period of peak viremia, both humoral and cellular 
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responses to HIV-1 can be detected[13-17], followed by partial control of viral 
replication and decreased levels of viremia. From two to eight weeks post infection, there 
is also a precipitous decline in CD4+ T cells in the blood. As viral replication drops, the 
CD4+ T cells are able to partially rebound. At this time, the disease is considered to have 
moved into the clinical latency stage where virus continues to replicate without causing 
symptoms of disease. This asymptomatic stage may last anywhere from months to years 
depending on a number of host factors.  
Unfortunately, without a cure for HIV infection, individuals infected with HIV 
face a lifelong dilemma of managing a chronic disease. Without pharmacologic 
intervention, viral load in almost all individuals will eventually rise with a corresponding 
drop in CD4+ cells in peripheral blood. Once the CD4+ T cells are at or below 200 
cells/µL blood, the patient is considered to have progressed to AIDS. Intense research 
over the years has developed numerous antiretroviral drugs targeting different stages of 
the viral life cycle, and the combination of several of these drugs has been successful in 
controlling viral replication when patients adhere to the treatment regimen. Antiretroviral 
therapy (ART) has advanced to the point where infected individuals can achieve a high 
quality of life and a normal lifespan; unfortunately, ART is expensive and also associated 
with toxicity and emergence of resistant viruses.  
 
Host response to early HIV-1 infection (humoral and cell-mediated) 
 Even at the start of the HIV pandemic, researchers were able to detect both 
humoral[13, 14] and cellular[15, 16] immune responses during the peak of plasma 
viremia in HIV-1 infection. Humoral immunity is the production of antibodies against an 
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antigen by plasma cells (effector B cells). “Neutralizing” antibodies are those that are 
able to prevent the biologic or pathologic effect of an antigen, such as preventing a virus 
from entering a cell, while “binding” antibodies are those that bind to the antigen and tag 
it to activate other cells of the immune system. Antibodies are developed against a variety 
of combinations of protein isoforms derived from the precursor polyproteins Gag, Env, or 
Pol[18]; however, the functional antibody isotopes seem to mostly be limited to those 
against a component of Env. The first antibodies produced are IgM isotype against the 
Env protein p41 before undergoing isotype switching to IgG and IgA.[18] Although these 
initial antibodies produced during acute viremia are successfully able to bind virus, they 
do not have a significant effect on plasma viral loads and are therefore not responsible for 
the initial control in viremia seen after the acute spike.[19] In natural HIV-1 infection, 
evidence suggests that neutralizing antibodies are not produced at the soon enough and in 
sufficient levels to account for the drop in HIV-1 replication seen after acute viremia. 
The cellular arm of host immunity has been identified as a major player in 
controlling early HIV-1 replication. Cellular immunity involves the activation and 
production of virus-specific CD8+ cytotoxic T lymphocytes (CTLs), macrophages, and 
natural killer (NK) cells and the release of cytokines. Cell-mediated immunity (CMI) is 
one of the most important defenses the host has against viral infection. Evidence has 
shown that CMI is crucial to partially controlling early viral replication, as HIV-specific 
cytotoxic T cell responses are temporally associated with a decrease in viral load.[17, 20, 
21] Also, the magnitude of the host’s CMI response to HIV-1 infection is inversely 
correlated with viral load.[21] 
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For T cells to become activated as CTLs, they must interact with cellular 
histocompatability proteins, which are transmembrane glycoproteins expressed on the 
surface of host cells. There are three categories of major histocompatibility (MHC) genes 
in vertebrates: class I, II, and III. Class I proteins present intracellular antigens on the cell 
surface, and are therefore important in host defense against intracellular pathogens, such 
as viruses or obligate intracellular bacteria. Class II proteins present extracellular 
antigens, and so are most important in host defense against extracellular pathogens. As 
almost all cells in the body are susceptible to viral infection, all nucleated cells express 
MHC class I markers on the surface of the cell. MHC class II markers are typically only 
present on professional antigen presenting cells (APCs), such as macrophages, dendritic 
cells, and B cells. Class III genes encode for proteins that have other varied functions in 
the immune system. 
The MHC class I is a heterodimer consisting of an alpha chain with 3 domains 
(α1- α3) and β2-microglobulin (encoded by a different gene). The α3 domain extends 
across the membrane, anchoring the complex in the cellular membrane. Domains α1 and 
α2 form a pocket, in the center of which is the peptide-binding groove, which can bind 
and present peptides 8-10 amino acids long. Ubiquitinated proteins within the cytoplasm 
of the cell are processed by the proteasome and shuttled to the endoplasmic reticulum 
(ER) lumen by the transporter associated with antigen processing (TAP). Once there, the 
peptide fragment is loaded by a polyprotein complex (including TAP, calreticulin, 
calnexin, Erp57, and tapasin) onto the still-assembling MHC class I glycoprotein. The 
peptide-MHC complex leaves the ER and moves to the Golgi via the secretory pathway, 
which transports it to the cell surface. 
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In a healthy cell, MHC class I will present peptides derived from cellular protein 
fragments that are produced by normal protein turnover (“self” antigens), which are 
subsequently ignored by immune surveillance T cells. When a host cell is infected with a 
virus, viral proteins are produced in the cytosol by cellular machinery during viral 
replication, and peptides derived from these viral proteins are loaded in MHC class I 
complexes and subsequently recognized by immune surveillance T cells. Specifically, the 
viral peptide in the context of MHC class I is recognized by the T cell receptor (TCR) on 
the surface of the naïve CD8+ T cell. Similar to antibodies, TCRs are comprised of 
proteins of the immunoglobulin superfamily. Most TCR molecules are comprised of α 
and β chains, each of which contains variable and constant regions. Like antibodies, 
diversity is created via V(D)J recombination, allowing for a huge range of antigen 
recognition. In order for the naïve T cell to recognize an antigen and become activated, 
the surface protein CD8 must bind the constant region of MHC class I. This close 
interaction allows for peptide recognition and activation of naïve CD8+ T cells into 
effector CTLs. 
Both MHC classes I and II are polygenic, encoded by multiple genes. MHC class 
I is encoded by three different loci, so each individual will express at least three different 
MHC class I molecules on all cells. In addition, they are extremely polymorphic with 
many amino acid variations in the α1 and α2 chains (the dimer forming the peptide-
binding grove), so each locus has many alleles. These alleles are also codominant. It is 
highly likely that any given individual will be heterozygous at each locus, therefore most 
individuals actually express six different MHC class I molecules (class I haplotype). This 
ensures that each individual will express multiple MHC alleles with different range of 
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peptide binding specificities, allowing for a wide range of peptide recognition, not only 
within one individual, but within the population as a whole. In humans, MHC class I is 
called human leukocyte antigen (HLA), and the three α-chain genes are HLA-A, HLA-B, 
and HLA-C. One of the most important host factors of disease resistance is an 
individual’s unique array of major histocompatibility alleles. This is especially relevant to 
HIV-1 pathobiology, as certain MHC class I alleles have been associated with decreased 
or increased progression to AIDS. 
 
Host determinants of disease progression and outcome 
 On average, the typical HIV-infected patient progresses to AIDS approximately 
one decade from the time of infection[22]. However, there is considerable variation from 
patient to patient. From the start of the AIDS epidemic, it quickly became apparent that 
host factors enabled some individuals to progress slower to AIDS than others. The term 
“long term nonprogressors” (LTNPs) typically refers to the small subset of HIV-1 
patients that have stable CD4+ counts without ART and a correspondingly benign course 
of disease over a long period of time.[23-26] LTNPs can represent anywhere from 2-5% 
of the total HIV-1 population.[25, 26] An even smaller group of individuals are able to 
completely control viral replication (<50 copies/mL); this group, comprising 
approximately only 0.3% of the HIV-1 infected population, is termed “elite suppressors” 
or “elite controllers”.[23, 26] In addition, some HIV-1 negative people (usually sex 
workers or partners of HIV-1 infected individuals) are termed “highly-exposed HIV 
seronegatives” because they never show evidence of infection despite repeated 
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exposures.[27-29] All of these different subgroups have been crucial in studying the 
potential mechanisms of effective host immunity against HIV-1 infection. 
 One of the earliest genetic factors of HIV resistance discovered was the 
importance of coreceptors in transmission. As mentioned previously, HIV requires CD4 
surface marker expression as well the presence of a chemokine coreceptor for the virus to 
enter the cell. This requirement for coreceptor binding explains the tropism that HIV 
shows for certain types of cells; for example, T cell tropic strains of HIV preferentially 
use the coreceptor CXCR4 (fusin), while macrophage tropic strains use CCR5.[30] 
Studies have also found CCR5 tropic viruses are prevalent in acute or asymptomatic 
infections while CXCR4 or dual tropic viruses (R5X4) are prevalent in progressive 
disease.[31-34] These observations have led to the conclusion that R5-tropic viruses are 
responsible for initiating infection within an individual. The importance of CCR5 in HIV 
transmission is further supported by the discovery of deletions in the CCR5 gene 
(CCR5Δ32) in some highly exposed HIV-seronegative individuals. Individuals that are 
homozygous for CCRΔ32 have nearly complete protection from infection, while 
individuals heterozygous for CCRΔ32 show delayed progression to AIDS.[35-37] 
Although the CCRΔ32 mutation is present at a relatively high frequency (5-14%) in 
European-descent populations, it is not found at all in African, Asian, and American 
Indian populations.[38] Therefore, although compelling, the CCR5Δ32 mutation only 
explains a small percentage of host resistance to HIV-1 infection. 
 There is a great deal of data pointing to CTL-mediated MHC class I dependent 
immunologic pressure as a crucial mechanism for HIV control. HLA-B*5701 and HLA-
B*27 MHC class I alleles in particular are historically overrepresented in LTNP and ES 
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groups.[23, 24, 39-41] The importance of the role of HLA haplotype in HIV-1 resistance 
was further confirmed with the International HIV Controllers Society genome-wide 
association study (GWAS), in which over 300 single nucleotide polymorphisms (SNPs) 
with genome-wide association to HIV progression were identified only within MHC-
I.[42] In addition, specific residues associated with immunologic control of HIV were 
localized to the peptide-binding groove of the MHC molecule. Multiple GWAS studies 
have been published to date, and the only significant associations found thus far have 
involved the HLA and chemokine regions of the genome, with HLA being the primary 
region affecting control of viral loads.[43] 
 
Viral antigenic variation 
 Ultimately, cell-mediated immunity and other host mechanisms are unable to 
eradicate HIV from the host. This is because HIV-1, like other retroviruses, is able to 
accrue massive genetic and antigenic variation that allows it to evade control from the 
host’s immune system, ART, or vaccine therapy. The is largely due to the fact that 
continuous replication occurring during the clinically latent phase using error-prone 
reverse transcriptase (RT) allows for huge numbers of point mutations to accumulate. 
This low replication fidelity is because RT lacks proofreading ability that cellular 
polymerases have. Although initial estimates from in vitro were higher[44], the error rate 
of HIV-1 is most likely somewhere around 1.4-3 x 10-5 errors per base pair, per 
replication cycle.[45] 
 Although many mutations in the HIV genome occur as a result of the high error 
rate of RT during viral replication, there are other ways HIV-1 generates genomic 
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diversity. One of the best known and most important is APOBEC3G, a member of the 
APOBEC family of cellular proteins that induces mutations in the HIV genome by 
deaminating cytosine residues to uracil in the minus-strand of viral DNA, resulting in a G 
to A mutation.[45, 46] Another major source of genetic variation in HIV-1 is viral 
recombination.[45, 47]. As with all other retroviruses, HIV-1 co-packages two viral RNA 
genomes in the capsid of one virion. During generation of viral DNA during reverse 
transcription, RT has been shown to be able to switch templates between co-packaged 
RNA at any point in the HIV genome, creating recombinant viruses. A single host cell 
must first be co-infected with more than one genetically distinct HIV and a virion must 
be packaged with one RNA genome from each distinct virus before true recombinant 
viruses can be created. Viral recombination is considered by some to have more of an 
evolutionary influence than mutation for several reasons: mutations are more likely to be 
harmful than beneficial, recombination can create new diversity by shuffling pre-existing 
mutations within a population and allows different areas of the viral genome to evolve 
independently, and recombination can combine beneficial mutations from different viral 
genetic lines into one.[45] 
Of particular interest to this project, viruses may escape CTL-mediated killing by 
accruing mutations that interfere with TCR recognition of viral peptide in the context of 
the MHC class I molecule. From the viral perspective, evasion from immune pressure 
may be accomplished by introducing viral peptide mutations that interfere with binding in 
the MHC peptide groove or mutations outside the epitope that alter the way that peptides 
are processed in the proteasome, thus affecting the ability of MHC class I to effectively 
present peptide for T cell recognition.[48]  
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 Mapping of CTL responses to HIV-1 epitopes has identified functional CTLs that 
recognize and respond to Gag epitopes (especially those localized to HIV Gag p24 
[capsid]), are associated with decreased viral load.[49-55] Furthermore, HLA alleles 
associated with slower or decreased progression to AIDS, such as HLA-B*5701, 
recognize peptides in Gag.[50, 55, 56] Although HLA-B*5701, B*27, and other HLA 
alleles are found in slow and non-progressors, not every individual that expresses these 
alleles will display this phenotype. This may be partially explained by the fact that 
individuals with “protective” alleles that go on to progressive disease do not have highly 
functional CTL responses (4 or more cytokines) against Gag p24.[49]  
There are several hypotheses that might explain specifically why Gag is so crucial 
to immunologic control of HIV-1. Not only is Gag very immunogenic, but also evidence 
suggests that Gag-specific CTLs are able to respond and kill viral infected cells sooner 
than CTLs directed against other HIV-1 epitopes, such as Env or Nef.[57] This may be 
due in part to the large relative abundance of gag proteins within the infected cell (~ 400 
molecules/cell compared to ~12 molecules/cell for RT).[58] The HIV-1 gag region of the 
genome is also a highly conserved region that encodes for main structural proteins.[56] 
The conserved nature of the Gag sequence implies that this is a region of the HIV-1 
genome that does not tolerate mutations well.  
The “fitness” of a virus is defined as the ability of that virus to successfully 
replicate when compared to a similar virus (e.g., two different strains), while the “fitness 
cost” refers to reduced replication as the result of escape mutations. Several lines of 
evidence provide support for the hypothesis that escape mutations in the Gag polyprotein, 
especially the capsid region, incur a fitness cost to the virus. Escape mutations found in 
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regions of Gag that are restricted by HLA molecules are frequently associated with 
decreased viral load.[40, 59-61] Also, in the macaque model of SIV infection, multiple 
studies have shown that escape viral mutations to epitopes in the capsid protein revert 
back to wildtype in the absence of MHC class I/CTL-mediated immune pressure.[62-64] 
For some mutations, looking at the protein structure of capsid in the region of the escape 
mutation has helped to explain subsequent fitness cost. Structural analysis of HIV-1 p24 
has shown that the canonical escape mutation T242N within the HLA-B*57/5801-
restricted Gag epitope TW10 reduces viral fitness because Thr-242 is critical for 
nucleating and stabilizing helix 6 in the capsid protein.[60]  
 Protective HLA alleles and viral escape mutations are not always associated with 
decreased disease progression. One possible explanation to this has been the observation 
that many viral escape mutations are accompanied by “compensatory” mutations that 
partially or completely restore viral fitness.[60, 61, 65-68] For example, escape within the 
HLA-B*5701-restricted Gag epitope TW10 is associated with several additional 
mutations within the CypA-binding loop of the capsid, and these mutations are more 
likely to be found in HLA-B*5701-positive individuals with progressive disease.[61] 
 
NeuroAIDS and HAND 
 Shortly after HIV-1 was identified as the cause of AIDS, physicians recognized 
that individuals with AIDS frequently demonstrated varying degrees of neurocognitive 
impairment (NCI). At that time, neurocognitive disorders were generally divided into two 
categories: 1) HIV-associated dementia (HAD), and 2) minor cognitive/motor disorder 
(MCMD).[69] Under current nosology, the broad spectrum of neurologic disease 
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associated with HIV-1 infection is referred to as HIV-associated neurocognitive disorders 
(HAND), which is further subdivided into HAD, MC/MD, and asymptomatic 
neurocognitive impairment (ANI).[69] The most severe manifestation, still generally 
referred to as HAD, is characterized by moderate to severe cognitive impairment that 
results in marked difficulty performing activities of daily living.[69] Before the advent of 
effective ART, HAD was recognized as a relatively common condition in HIV-infected 
individuals, especially those with low CD4+ counts and high viral load. After 
introduction of effective ART, the incidence of HAD has drastically decreased along with 
the incidence of AIDS.[69, 70] Unfortunately, mild and moderate forms of HAND have 
persisted despite successful ART, and amongst the mildest forms of HAND, the overall 
incidence of NCI has actually increased in the post-ART era compared to the pre-ART 
era.[70] The 2010 CHARTER study reported that overall 52% of HIV-1 infected 
individuals had some level of NCI; of these, only 7% were diagnosed with HAD, 12% 
had mild NCI, and 33% had evidence of asymptomatic NCI.[70] 
 Despite the recognition of chronic neurologic disease as an important 
manifestation of HIV infection, the pathogenesis of HAND in successfully ART-treated 
individuals continues to be elusive. There are numerous possible explanations, including 
the legacy effect (viral or inflammatory-mediated damage prior to initiation of therapy), 
immune restoration disorder, host genetic factors, and poor CNS penetrance of ART.[71, 
72] Most likely, HAND is the end result of multiple pathophysiologic factors that 
contribute to a complex neurobehavioral outcome. A recent Multicenter AIDS Cohort 
Study GWAS was unsuccessful in finding an impact of relatively common genetic 
variations on the risk for developing HAND.[71] Furthermore, the clinical observations 
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that define HAND are not pathognomonic for HIV-1 infection, and a fairly large 
proportion of HIV seronegative individuals fit these criteria, implicating co-morbidities 
in addition to HIV damage.[71] The continued high prevalence of HAND in the post-
ART era is especially concerning because these individuals have poorer clinical 
outcomes, with higher mortality, lower quality of life, and worse adherence to 
treatment.[72]  
 
CTLs and NeuroAIDS 
 Although some systemic effects of HIV-1 infection likely affect the nervous 
system, the virus itself directly infects the CNS with productive infection of microglia 
and perivascular macrophages and nonproductive infection of astrocytes.[73-75] 
Characteristic histopathologic lesions of HIV-1 associated encephalopathy include 
multifocal giant cell encephalitis (MGCE), characterized by perivascular macrophages 
and multinucleated giant cells harboring replicating HIV-1, as well as a progressive 
diffuse leukoencephalopathy (PDL) with myelin loss, astrocyte proliferation, and 
histiocytic parenchymal infiltrates.[76] One theory is that mild and moderate forms of 
HAND are at least in part due to chronic neuroinflammation as the result of persistent 
HIV-1 replication.[71, 72] 
 Given the importance of CTLs in host immunologic control of early HIV-1 
infection in the periphery, CTLs also likely play an important role in the pathogenesis of 
HIV-associated neurologic disease. Indeed, perivascular CD8+ T cells have been 
demonstrated in the brains of patients with HIV-associated encephalitis (HIVE)[77-80], 
which suggests that CTLs may be important in controlling HIV replication in the brain. 
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CTLs directed against HIV-1 are also believed to infiltrate the brain early in infection, as 
CD8+ T cells are found in the brains of individuals that have not yet developed 
disease.[80] These findings are also supported by findings from primate models of 
neuroAIDS. Rhesus macaques (Macaca mulatta) infected with a macrophage tropic 
strain of simian immunodeficiency virus showed massive increases in the number of 
CD8+ T cells in the brain as well as increased expression of cytolytic enzymes 
(granzymes, perforin, IFNγ).[81-83] On the other hand, it is possible that CTL-mediated 
viral control may be acting as a double-edge sword by contributing to neuropathology 
through cytotoxic granule release and CTL-mediated neuronal death.[77] 
 As the CNS is one of the most difficult systems to monitor disease progression in 
detail due to limited accessibility, there are significant challenges in studying HIV 
pathogenesis in the brains of human patients. For this reason, primate models of 
retroviral-associated encephalitis have been invaluable in studying neuroAIDS in depth 
and longitudinally. 
 
Simian immunodeficiency virus 
 Simian immunodeficiency virus (SIV) is the most closely related retrovirus to 
HIV. HIV-1 is believed to have arisen from SIV found in chimpanzees (SIVcpz) as the 
result of at least three independent cross-species transmission events, most likely from 
exposure to infected blood from bushmeat.[84] Similarly, HIV-2 is believed to have 
arisen from SIV in West African sooty mangabeys (SIVsm).[85, 86] Despite high 
circulating viremia, SIVs in these natural hosts do not generally cause disease.[87] 
Shortly after the AIDS epidemic in people began, a similar syndrome was observed in 
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several different groups of captive Asian macaques[87], including a small group of 
rhesus macaques.[88, 89] These Asian animals, which were not endemically infected 
with SIV, turned out to be infected with SIVmac, which was later found to be closely 
related to HIV-2 and HIVsm.[85] It was quickly realized that Asian macaques were 
susceptible to SIV and develop an immune syndrome very similar to HIV/AIDS while 
the natural African primate hosts generally do not. SIV is estimated to have been in 
African primates for over 32,000 years, so it is highly likely that host adaptation (host 
and virus coevolution) is responsible for its low pathogenicity in host species.[90] Since 
the discovery of SIV, a variety of different SIV strains in different primate species have 
been used as animal models to recapitulate various features of HIV infection in humans. 
   
Primate models of SIV-associated encephalitis 
 Animal models are particularly useful in studying the neuropathogenesis of HIV 
because of CNS sample availability at any time point throughout infection. Most primate 
models of AIDS have used rhesus macaques (Macaca mulatta), and most primate models 
of neuroAIDS have used either SIVmac239 or SIVmac251, both of which are R5-tropic 
(like almost all SIV strains) and cause acute viremia.[91] Both viruses are also capable of 
inducing meningitis, although only SIVmac251 causes encephalitis and glial activation in 
the neuropil characteristic of human HIVE.[91] Although SIVmac251 provides an 
excellent model for HIV neuropathogenesis, there are several limitations: only 
approximately one quarter of animals infected will actually progress to develop 
encephalitis, and the time frame is long, taking two years or more, for the development of 
AIDS.[91] For this reason, several accelerated models of SIVE have been established. 
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In one model, classic retroviral encephalitis can be induced in up to 90% of rhesus 
macaques by using monoclonal antibodies to deplete CD8+ T cells.[92-94] This model 
also serves to highlight the importance of CTL immunologic control in the development 
of HIVE, although it is somewhat limited because entire subsets of immune cells (CD8+ 
T cells and NK cells) are eliminated. Another method that researchers have used to 
reliably induce SIV-encephalitis (SIVE) is to develop neurotropic (able to infect cells in 
the CNS) and neurovirulent (able to induce neuropathology) strains of SIV. Macrophage 
tropism has long been known to play an important part in the development of HIVE[95, 
96], although studies have shown that macrophage tropism alone is not sufficient to 
induce the development of neurologic disease.[97] Studies with recombinant SIV indicate 
that portions of the env gene impart macrophage tropism, but that complete env, nef, and 
3’LTR sequences are necessary for neurovirulence.[97, 98] 
The Retrovirus laboratory at Johns Hopkins University developed another primate 
model of accelerated neuroAIDS by dual inoculating pigtailed macaques with a 
neurovirulent molecular clone (SIVmac/17E-Fr) and an immunosuppressive swarm 
(SIV/DeltaB670). Using this combination, 70-90% of pigtailed macaques develop classic 
retroviral encephalitis and all animals develop AIDS-defining criteria within three 
months.[99, 100] Although most studies of SIV pathogenesis have been done using 
rhesus macaques, pigtailed macaques have proven to develop more rapid, more severe 
neurologic disease when compared with rhesus macaques given the same SIV inoculum. 
 
Neuroprotective host factors and viral escape in pigtailed macaques 
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 Another reason that nonhuman primate models of HIV pathogenesis have proved 
invaluable is macaque genetic complexity and associated wide range of host responses to 
viral infection. Macaques have a larger number of MHC class I alleles than humans, and 
some alleles have been identified that are associated with altered progression to 
AIDS.[101] In rhesus macaques, the MHC class I alleles Mamu-A*01 and –B*17 have 
been correlated with decreased viral load and increased survival time.[102-105] The 
immunodominant SIV epitope restricted by Mamu-A*01 (CM9, CTPYDINQM181–189) is 
in the same highly conserved region of Gag capsid as HIV TW10, which is restricted by 
HLA-B*57.[106-108] This provides an invaluable tool to study CTL-mediated 
immunologic control; however, the supply of rhesus macaques for research is limited, 
and it has become increasingly difficult to obtain Mamu-A*01-positive rhesus for 
research for a variety of reasons.[109, 110] 
Pigtailed macaques also show similar MHC class I allele-associated protection. 
Expression of the allele Mane-A1*084:01:01 (formerly Mane-A*10) is associated with 
lower viral load and this protein presents the immunodominant Gag capsid epitope KP9 
(KKFGAEVVP164-172), a region that overlaps with HIV Gag KF11 (an immunodominant 
epitope recognized by HLA-B*5701).[110, 111] Furthermore, MHC class I-mediated 
immune pressure at that epitope rapidly induces the formation of a canonical lysine to 
arginine escape mutation (K165R). Using the accelerated model of neuroAIDS in 
pigtailed macaques, our lab has demonstrated a neuroprotective effect of MHC class I 
allele expression; animals that express Mane-A1*084:01:01 are much less likely to 
develop SIV encephalitis (SIVE) than animals that do not.[112, 113] This is the first time 
that HIV/SIV-induced organ-specific disease outcome has been shown to be altered by 
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MHC class I expression. This finding helps explain the fact that, although all dual-
inoculated animals go on to develop high viral loads and progress to AIDS, a small 
proportion of animals consistently do not develop encephalitis.  
Interestingly, Mane-A1*084:01:01 positive macaques with the highest CNS viral 
loads developed the prototypic K165R Gag escape as previously found in the plasma in 
pigtailed macaques inoculated with SIVmac251[112], raising the question of how large a 
role escape mutations play in the development of SIVE. Longitudinal sequencing of 
plasma and CSF in these animals also showed SIV K165R Gag escape prevalence 
increases over time, and that this is driven by KP9-specific CTL pressure.[113] In 
addition, SIV K165R Gag escape mutations were archived in latent proviral DNA 
reservoirs, including the brain in animals receiving HAART that suppressed viral 
replication.[113] Replication-competent SIV Gag K165R escape mutations were present 
in the resting CD4+ T cell reservoir in HAART-treated SIV-infected macaques, 
indicating that escape develops during the decaying phases of viremia and then can 
persist in latent reservoirs, including the brain.[113] 
 
Project goals 
Despite the provocative relationships between MHC class I alleles and the 
development of AIDS, associations between the expression of MHC class I alleles and 
HIV-induced organ-specific disease outcomes, including HAND, have not been 
investigated. In addition, the relationship between CTL escape and HIV CNS disease 
remains poorly understood. It is likely that viral fitness in the CNS is distinct from fitness 
in the periphery given numerous studies that have shown neurovirulent HIV and SIV 
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contain signature changes in many genes that differ from virus replicating in the 
periphery.[95, 97, 114] In addition, it is likely that viral escape can arise in the CNS 
independent of the periphery because different selective pressures on virus evolution 
exist in the CNS versus the periphery. The overarching goal of the proposed studies was 
to establish the foundation for novel immunomodulatory therapies targeting the CNS by 
gaining an understanding of how host genetics and manipulation of cell-mediated 
immune responses alters progression of SIV-induced CNS disease.   
A large part of understanding host genetics and disease resistance is 
understanding species differences in disease progression. Chapter II focuses on the 
inherent differences and similarities between rhesus and pigtailed macaques within the 
confines of the same accelerated CNS disease paradigm. In a retrospective study, we 
directly compared disease progression in 44 pigtailed macaques versus 29 rhesus 
macaques that were dual-inoculated with SIV/17E-Fr (neurovirulent clone) and 
SIV/DeltaB670 (immunosuppressive swarm). Despite the emergence of pigtailed 
macaques as an increasingly popular animal model to study HIV pathogenesis, few other 
groups have looked at the inherent differences between this species and Indian-origin 
rhesus macaques (the most frequently used animal model historically). We found that 
SIV infection results in faster progression to AIDS in pigtailed macaques and a greater 
decline in CD4+ lymphocytes compared to rhesus macaques. In addition, pigtailed 
macaques have consistently higher viral loads in both plasma and cerebrospinal fluid than 
rhesus macaques and more frequently develop SIVE (as measured by the presence of 
multinucleated giant cells and perivascular histiocytic cuffing on histopathologic 
examination). We also investigated the comparative roles that protective MHC class I 
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allele expression plays in each species, and we found that Mane-A1*084:01:01 
expression in pigtailed macaques and Mamu-A*01 expression in rhesus are both 
associated with decreased progression to SIVE, although the effect is stronger in pigtailed 
macaques.  
In chapter III we examined the specific effects that KP9 CTL-mediated 
immunologic control has on viral escape and disease outcome in our well characterized 
pigtailed macaque model. We produced a molecularly cloned SIV/17E-Fr K165R Gag 
escape mutant virus by inserting the K165R mutation into the neurovirulent clone, 
SIV/17E-Fr using site-directed mutagenesis to understand the potential fitness cost of this 
escape mutation as it pertains to neurovirulence. The first aim in this study was to 
determine the relative fitness of SIV/17E-Fr K165R Gag escape compared to wildtype 
SIV/17E-Fr. To compare the in vitro fitness of these viruses, we performed competition 
assays in multiple primary cell lines. Competition assays in CEMx174 cells (hybrid T/B-
cell human cell line susceptible to HIV/SIV infection) as well as primary cultured 
microglia, macrophages and lymphocytes, and demonstrated that, 1) the cloned SIV/17E-
Fr K165R virus replicates successfully in all cell lines tested, and 2) there appears to be a 
fitness cost to escape, as SIV/17E-Fr K165R replicated at lower levels and more slowly 
than wildtype SIV/17E-Fr. 
We expanded these studies in vivo by inoculating pigtailed macaques with 
molecularly cloned SIV and longitudinally tracked viral load, plasma CD4+ levels, and 
reversion of Gag K165R to wildtype Gag KP9. In total, six pigtailed macaques that 
expressed the allele Mane-A1*084:01:01 were inoculated: three with wildtype SIV/17E-
Fr, and three with SIV/17E-Fr K165R. We found that there was no difference between 
	   28	  
plasma viral loads in animals inoculated with a virus containing wildtype Gag KP9 or 
escape Gag K165R, but animals inoculated with SIV/17E-Fr K165R had a slightly lower 
CSF viral load than those inoculated with wildtype SIV/17E-Fr. Most interestingly, 
reversion to wildtype SIV/17E-Fr was noted at day 7 p.i. in the CSF only in two animals 
inoculated with SIV/17E-Fr K165R, suggesting that viral fitness in the CNS is different 
from the periphery. 
The second aim in chapter III was to longitudinally track in vivo Gag and Tat 
peptide-mediated CTL recognition, reversion, and compensatory mutations, and 
determine if there was a shift in CTL focus from the immunodominant SIV Gag epitope 
in Mane-A1*084:01:01 animals inoculated with SIV/17E-Fr K165R. We found that these 
animals shifted their functional CTL response from Gag KP9 to a co-immunodominant 
epitope in SIV Tat (KVA10), although there was no evidence of escape at the new locus. 
In addition, we found no evidence of compensatory mutations in the region of Gag KP9, 
in contrast to what was reported by Reece et al in a similar animal model.[115] 
In continuation with our ongoing characterization of KP9 escape in Mane-
A1*084:01:01 positive pigtailed macaques, we tested a vaccine with the purpose of 
stimulating cell-mediated immunity against Gag KP9 in the hopes of decreasing SIV-
associated neurologic disease. In collaboration with Raphael Viscidi at the Johns Hopkins 
School of Public Health, we primed, boosted, and challenged two monkeys with a novel 
virus like particle (VLP) vaccine platform[116] that presents SIV Gag KP9. Both animals 
successfully developed detectable Gag KP9 tetramer-positive CTL responses before 
challenge with the neurovirulent clone SIV/17E-Fr. Although there was no difference 
between the plasma viral load, the vaccinated animals showed lower longitudinal CSF 
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viral loads than control animals, further suggesting CTL-mediated viral control is 
different in the CNS when compared with the periphery.  
 
Conclusions 
 Although new antiretroviral drugs continue to be developed, no antiretroviral 
therapy has been able to provide a cure. Unfortunately, vaccine trials have met with 
limited success. To date, nonhuman primates remain the best animal model of HIV/SIV 
to study either prophylactic or therapeutic vaccines. Although any preventative vaccine 
will likely require multiple approaches to be maximally successful at preventing and 
controlling infection, studies in primates have suggested that therapeutic vaccines will 
need to target Gag in order to be successful in controlling chronic viremia.[117] This 
work shows that SIV Gag specific CTL-mediated immunologic control of viral infection 
is important to organ-specific pathogenesis, targeted immune pressure drives viral escape 
that has a detrimental effect on viral replication, and that immunologic pressure on a 
highly conserved epitope in Gag is unique in the CNS when compared to the periphery. 
As therapeutic vaccination strategies to enhance CTL responses against HIV Gag could 
promote HIV escape, it is vital that we understand the consequences of viral escape on 
disease progression, especially in the CNS. Our studies have significantly improved our 
understanding of how CMI alters progression of SIV-induced neurologic disease, 
establishing the foundation for novel immunomodulatory therapies targeting the CNS in 
HIV infection.   
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Introduction 
Given the similarities between simian immunodeficiency virus (SIV) and HIV, 
SIV/macaque models have been valuable for elucidating HIV pathogenesis, testing 
therapeutics, and vaccine development. The most widely used species for SIV studies 
include rhesus macaques (Macaca mulatta) and pigtailed macaques (Macaca 
nemestrina). Although SIV inoculation of Indian-origin rhesus macaques is the most 
common and best characterized primate model of HIV infection, limited availability of 
these animals has prompted interest in alternate macaque species for SIV studies.[1] In 
particular, pigtailed macaques have gained in popularity as a primate model of HIV 
pathogenesis because of their larger size, tractable temperament, and susceptibility to SIV 
infection.[2] Previous studies have also suggested not only that SIV infection in pigtailed 
macaques more closely recapitulates HIV infection in humans, but that pigtailed 
macaques are also more likely to progress to SIV-associated encephalitis than rhesus 
macaques.[3, 4] 
In parallel with the discovery that certain MHC class I alleles in humans were 
associated with altered progression from subclinical infection to AIDS[5], similar 
relationships were identified in SIV/macaque models of HIV. MHC class I alleles of 
rhesus macaques (Macaca mulatta) in particular have been well characterized[6-9] with 
discovery of MHC class I alleles, such as Mamu-B*17, Mamu-A*07, and the most 
studied, Mamu-A1*001, that are associated with increased viral control and decreased 
progression to AIDS.[9-14] Like humans and rhesus macaques, individual MHC class I 
alleles in pigtailed macaques that present SIV peptides to cytotoxic T cells have been 
characterized.[15-17] Of these, the pigtailed macaque MHC class I allele Mane-
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A*084:01 (formerly named Mane-A*10) has been associated with lower peak viral load 
and decreased progression to AIDS in animals inoculated with SIVmac251.[2] In our 
well-characterized model of HIV CNS disease in pigtailed macaques inoculated with 
both SIV/17E-Fr and SIV/DeltaB670, we have found that Mane-A*084:01 is a 
neuroprotective allele that is associated with decreased progression to SIV CNS disease 
independent of influencing plasma viral load.[15, 16] Interestingly, Mane-A*084:01 
recognizes an immunodominant SIV Gag epitope KP9 that is homologous to the HIV 
Gag epitope KF11, which is restricted by HLA-B*57:01 in humans.[17, 18]  
Few studies have directly compared SIV disease progression between rhesus and 
pigtailed macaques[2, 19, 20], and no studies have reported in detail whether the 
induction of SIV CNS disease varies between these two species. Although advances in 
HIV treatment have dramatically reduced the incidence of HIV-associated dementia 
(HAD), neurocognitive defects in treated HIV infected individuals persist, manifest as 
less severe HIV-associated neurocognitive deficits (HAND).[21] SIV/macaque models 
will be essential for establishing the causes of HAND.  
The SIV pigtailed macaque model developed at Johns Hopkins recapitulates key 
features of HIV-associated neurologic disease, including high viral load in the 
cerebrospinal fluid (CSF), encephalitis[4, 22, 23], as well as PNS damage [24, 25], and 
therefore serves as the basis for comparison with disease progression in rhesus macaques 
inoculated with the same SIV combination. To investigate whether host factors regulate 
SIV CNS disease progression, we compared the course of disease and the incidence of 
SIV encephalitis (SIVE) in rhesus and pigtailed macaques that were dual-inoculated with 
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This retrospective study included 44 pigtailed macaques (Macaca nemestrina) 
and 29 rhesus macaques (Macaca mulatta) that were intravenously inoculated with 
SIV/DeltaB670 (50 AID50) and SIV/17E-Fr (10,000 AID50) as previously described.[4] 
Animals were perfused with sterile saline at euthanasia to remove blood and circulating 
virus from brain. Animals were MHC class I typed by sequence-specific primer (SSP)-
PCR.[15] By design, pigtailed macaques were euthanized at approximately 84 days post-
inoculation or at the onset of AIDS-defining illness (whichever came first) given 
consistent progression to AIDS at this timepoint. Initially, 3 rhesus macaques were 
euthanized at day 84 post-inoculation to compare directly with pigtailed macaque studies. 
As these three rhesus macaques did not develop either AIDS or CNS disease, the 
subsequent 26 rhesus macaques were euthanized at the onset of AIDS-defining illness, 
which ranged from 36 to 560 days PI. Animals were euthanized if any two of the 
following occurred: weight loss greater than 15% of baseline, clinical signs of organ-
specific disease (i.e., CNS, lung, etc.), intractable diarrhea, or opportunistic infection. All 
animal procedures in this study were performed according to the principles set forth by 
the Institutional Animal Care and Use Committee at Johns Hopkins University and the 
National Research Council’s Guide for the care and use of laboratory animals. 
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Quantitation of SIV RNA 
To quantitate ongoing viral replication in infected animals, SIV RNA in plasma, 
CSF, and tissues was measured by qRT-PCR using primers in the SIV gag region, as 
previously described.[16, 26] Briefly, the primers used to detect unspliced viral RNA 
were: forward primer, SGAG03, 5’-CAGGGAAIIAAGCAGATGAATTAG-3’; reverse 
primer, SGAG04, 5’-GTTTCACTTTCTCTTCTGCGTG-3’; and probe, pSUS05, 5’-(6-
carboxyfluorescein [FAM])ATTTGGATTAGCAGAAAGCCTGTTGGAG (6-
carboxytetramethylrhodamine [TAMRA])-3’ with cycle conditions of 50°C for 30 min, 
94°C for 15 min to reverse transcribe RNA, which was followed by 45 cycles of PCR at 
94°C for 15 s, 55°C for 15 s, and 60°C for 30 s (detection limit 100 copies/mL).[16] 
 
Histopathology 
Sections of brain were scored for the presence of encephalitis as previously 
described.[27] SIV-associated encephalitis was defined as multifocal perivascular 
accumulations of macrophages and multinucleated giant cells and glial nodules. 
Hematoxylin and eosin stained sections of frontal and parietal cortex, basal ganglia, 
thalamus, midbrain, and cerebellum were scored in a blinded fashion. Mild encephalitis 
was classified as those animals who had an average of less than 10 macrophage-rich 
perivascular cuffs, moderate encephalitis scores were those animals with an average of 10 
to 30 perivascular cuffs, and severe encephalitis were animals with an average of more 
than 30 perivascular cuffs.[27] 
 
Immunohistochemical staining and quantitative image analysis 
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Macrophage activation and infiltration in the brain was quantified by 
immunohistochemistry using a primary antibody against CD68 (KP-1, diluted 1:2,000, 
DAKO, Carpinteria, CA) on standardized coronal sections of brain including basal 
ganglia and frontal cortex. Immunohistochemical staining and standardized sampling was 
done as previously described.[28] Twenty adjacent fields in the subcortical white matter 
subjacent to the cingulate gyrus were captured at 200X magnification (an area of ~3 
mm2) using a Nikon DS-Ri1 digital camera (Nikon, Tokyo, Japan). These images were 
binarized and the area fraction of immunopositive pixels was calculated using Nikon 
Elements to enumerate the area occupied by CD68 positive macrophages. 
 
Statistical analysis 
Survival curves for pigtailed macaques and rhesus macaques up to day 84 post-
inoculation were compared by the Gehan-Breslow-Wilcoxon test.  Similarly, groupwise 
comparisons of plasma and CSF viral load, CD4+ T cell counts, and CSF IL-6 and 
CCL2, and terminal tissue viral load were performed using the two sample nonparametric 
Mann-Whitney t-test. The Fisher’s exact test (one-sided) was used to identify 






	   51	  
Results 
Accelerated progression to AIDS with a greater decline in CD4+ lymphocytes in 
pigtailed macaques compared to rhesus macaques 
All pigtailed macaques developed AIDS-defining criteria by approximately 84 
days p.i. with a steady decline in CD4+ T cells from day 45 onwards (Fig. 1a). In 
contrast, rapid progression to AIDS in rhesus macaques was much less common; 
although four rhesus macaques progressed rapidly (<60 days p.i), AIDS developed in 
most rhesus macaques from 120 to 350 days p.i. 
To compare kinetics of immunosuppression after SIV infection, we measured 
CD4+ T cell counts in blood longitudinally in all animals, revealing a greater decline 
from baseline in CD4+ T cells in pigtailed macaques compared to rhesus macaques (Fig. 
1b). When measured at day 84 p.i., rhesus macaques had the same absolute CD4+ T cell 
count as pigtailed macaques, however rhesus macaques had a significantly lower terminal 
absolute CD4+ lymphocyte count than pigtailed macaques (P=0.0003, Mann-Whitney t-
test). The nadir median CD4+ cell count in rhesus was reached at >300 days p.i., 
consistent with a more protracted course of disease progression in rhesus macaques than 
pigtailed macaques. 
 
Pigtailed macaques consistently developed higher viral loads in both plasma and 
cerebrospinal fluid than rhesus macaques 
SIV viral load was measured in both the plasma and CSF of all animals 
throughout the course of infection (Fig 2a,b). Pigtailed macaques had a significantly 
higher viral load than rhesus at day 84 p.i. in both plasma (Fig 2c; P=0.0002, Mann-
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Whitney t-test) and CSF (Fig 2d; P=0.0093, Mann-Whitney t-test). Even with the 
extremely long study duration of rhesus macaques compared to pigtailed macaques, 
terminal viral loads were higher in pigtailed macaques than in rhesus macaques in the 
plasma (P=0.0092, Mann-Whitney t-test) and CSF, where the difference approached 
significance (P=0.0619, Mann-Whitney t-test). 
 
Pigtailed macaques developed SIV-induced CNS disease more frequently than 
rhesus macaques 
 To quantify the incidence and severity of SIV-induced CNS disease, the CNS of 
all animals were scored for the presence of classic SIV encephalitis defined by presence 
of perivascular cuffs of macrophages, multinucleated giant cells and scattered glial 
nodules. Pigtailed macaques trended to develop SIV encephalitis more frequently than 
rhesus macaques. (Table 2; P=0.0686, one-sided Fisher’s exact test). Correspondingly, 
pigtailed macaques had higher levels of CCL2 (MCP-1) in the CSF than rhesus macaques 
during both acute (Fig 3b; P=<0.0001 at d7 p.i, Mann-Whitney t-test) and chronic phases 
of infection (P=0.046 at d84 p.i., Mann-Whitney t-tests). In addition, when terminal CSF 
CCL2 levels were compared, CCL2 was significantly higher (P=0.045, Mann-Whitney t-
test) in pigtailed macaques compared to rhesus macaques. CSF IL-6 levels in pigtailed 
macaques were slightly higher than rhesus macaques in acute (P=0.13 at d7 p.i., Mann-
Whitney t-test) and chronic (P=0.22 at d84 p.i., Mann-Whitney t-test) stages of infection, 
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Comparable terminal tissue SIV RNA levels in pigtailed macaques and rhesus 
macaques 
To compare extent of viral replication in peripheral tissues and the CNS at 
terminal timepoints, we measured SIV RNA levels in the spleen and basal ganglia (Fig 
4a,b) from rhesus macaques and pigtailed macaques. While viral RNA levels were higher 
in both the spleen and basal ganglia of pigtailed macaques compared to rhesus, there was 
not a significant difference between the two groups. 
 
MHC class I alleles play an important role in the development of SIV-encephalitis in 
both pigtailed macaques and rhesus macaques 
To determine whether host genetics contribute to the progression of neurologic 
disease across macaque species, we genotyped all animals for expression of MHC class I 
alleles previously associated with lower plasma viral loads including Mamu-A1*001 in 
rhesus macaques and Mane-01*084:01:01 in pigtailed macaques. 5 of 29 (17%) of rhesus 
macaques expressed Mamu-A1*001; 14 of 44 (32%) of the pigtailed cohort expressed 
Mane-01*084:01:01 (Table 3). In pigtailed macaques, Mane-01*084:01:01 expression 
was not associated with altered plasma or CSF viral loads (Fig 5b,d). In contrast, rhesus 
that expressed Mamu-A1*001 had significantly lower terminal plasma viral load (Fig 5a; 
P=0.0190, Mann-Whitney), but viral load in the CSF was not associated with this MHC 
class I allele (Fig 5c; P=0.3710, Mann-Whitney).  However, both rhesus macaques that 
expressed Mamu-A1*001 and pigtailed macaques expressing Mane-01*084:01:01 had 
lower levels of SIV RNA (P=0.0107 and P=0.0568, respectively, Mann-Whitney) in the 
brain consistent with MHC class I-mediated neuroprotection (Fig 5e and 5f).  
	  
	   54	  
 
Discussion 
 Rhesus macaques and pigtailed macaques have proven to be valuable animal 
models of HIV due to their susceptibility to SIV; however, few studies have directly 
compared SIV outcomes in these two different macaque species. Over the last 20 years, 
we have studied a large number of pigtailed and rhesus macaques that were inoculated 
with the same SIV combination, allowing us to compare retrospectively a large number 
of animals. Based on our observations and the observations of others[2, 4], we 
hypothesized that rhesus macaques would progress to AIDS more slowly and develop 
SIVE less frequently. In addition, we hypothesized that the immunodominant MHC class 
I allele Mamu-A1*001 would show similar neuroprotective effects in rhesus macaques as 
the immunodominant allele Mane-A1*084:01:01 has been shown in pigtailed 
macaques.[15]  
As expected, pigtailed macaques progressed to disease more rapidly than rhesus 
macaques, shown by shorter survival, higher longitudinal plasma and CSF viral loads, 
and a greater drop in CD4+ cells before d84 p.i. in pigtailed macaques compared to 
rhesus. At terminal time points, plasma and CSF viral loads (P=0.0092 and P=0.062 
respectively, Mann-Whitney) as well as SIV RNA levels in spleen and brain (P=17 and 
P=0.23 respectively, Mann-Whitney) were lower in rhesus macaques than pigtailed 
macaques. With this in mind, it is not surprising that our cohort of pigtailed macaques 
died or were euthanized due to AIDS-defining illness much earlier than rhesus. It was 
initially suspected that rhesus macaques would have a relatively similar course of 
infection as pigtailed macaques; however, when the first three animals (12L, 21M, and 
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23M) were dual-inoculated and then euthanized at the time that pigtailed macaques have 
progressed to AIDS, none of these animals had developed encephalitis or AIDS-defining 
illnesses. Thus, subsequent rhesus macaques were allowed to progress until the 
development of AIDS-defining illness, which in many animals did not occur until after 
200 days post inoculation. 
 Consistent with previous findings in both rhesus and pigtailed macaques[2, 19, 
29-31], we found decreases in CD4+ T cell levels in both species after SIV inoculation; 
however, there was a much greater decrease in CD4+ T cells from baseline in pigtailed 
macaques. Pigtailed macaques also showed a classic pattern of acute CD4+ T cell 
decrease followed by a slight rebound then a progressive loss of CD4+ T cells over time. 
Conversely, rhesus macaques had an initial drop that was maintained within the 84-day 
post-inoculation time span. The median CD4+ T cell levels then continued to decline 
over time as animals progressed past 500 days, indicating again that rhesus macaques 
progressed more slowly compared to pigtailed macaques, even with a relatively virulent 
inoculation. 
Consistent with our hypothesis, we showed that rhesus macaques did not develop 
neurologic disease as frequently as pigtailed macaques. With the dual-inoculum of 
SIV/17E-Fr and SIV/B670, 64% of pigtailed macaques developed SIVE compared to 
42% of rhesus, although the mean time to euthanasia for rhesus macaques (201.3 days) 
was substantially longer than pigtailed macaques (79.7 days).  We also compared several 
well-defined markers of SIV CNS disease, CSF IL-6 and MCP-1, both of which predict 
the development of SIVE.[27] Pigtailed macaques had higher IL-6 and MCP-1 in the 
CSF at acute (d10 p.i.) and chronic (d42 p.i. and beyond) time points. Terminal CSF IL-6 
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levels in rhesus were the same as in pigtailed macaques, consistent with prolonged 
disease progression in rhesus macaques. Terminal CSF MCP-1 levels were still 
significantly higher in pigtailed macaques than rhesus.   
Recently, Klatt et al performed a retrospective study that compared SIVmac239 
infection in rhesus macaques versus pigtailed macaques. Although pigtailed macaques 
developed AIDS more rapidly than rhesus macaques, they did not have a correspondingly 
higher viral load, in contrast to our study.[2] Previously, Polacino et al compared 
SHIVSF162 P4 infection in pigtailed and rhesus macaques, and concluded that pigtailed 
macaques had significantly higher peak and setpoint plasma viral loads as well as a 
significantly higher proportion of animals that showed persistent viremia.[20] Similar to 
the findings of Polacino et al, our group of SIV-inoculated pigtailed macaques had higher 
viral loads in plasma and CSF than rhesus macaques. Additional important differences 
between our study and previous reports include persistent viremia with much higher 
plasma viral loads, and uniform progression to AIDS-defining illness in all pigtailed 
macaques in a relatively short time frame. This is likely due to the high virulence of the 
inoculum used in our cohort. All animals in our cohort were dual-inoculated with both a 
macrophage-tropic, neurovirulent clone as well as an immunosuppressive swarm, as 
opposed to single inoculation with cloned SIVmac239. 
In a study comparing neuropathogenesis of rhesus and pigtailed macaques 
inoculated with a simian-human immunodeficiency virus (SHIV)(KU-2), 21 of 22 
pigtailed macaques failed to develop SHIV-associated neurologic disease with productive 
CNS viral replication; however, this was believed to be due to the inherent failure of the 
SHIV to replicate in pigtailed macaque macrophages, while the virus was macrophage 
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tropic in rhesus, leading to effective CNS viral replication in most animals.[32] 
Macrophage tropism has been well established as a pre-requisite for SIV or SHIV strains 
to cause lentiviral-associated neurologic disease in either rhesus or pigtailed 
macaques.[32-35] This is the first study to directly compare the pathogenesis of rhesus 
and pigtailed macaques challenged with a very neurovirulent SIV inoculum. 
 To compare the effects of host genetics on disease progression, we focused on the 
most well characterized MHC class I allele in each animal: Mamu-A1*001 in rhesus and 
Mane-A*084:01:01 in pigtailed macaques. Proportions of macaques that expressed each 
allele in our population is similar to what has been reported for each species, although 
there is a large amount of variation in Mamu-A1*001 expression between different wild 
and captive populations of rhesus macaques. 31.8% of the pigtailed macaques in this 
study expressed Mane-A*084:01:01, closely following the 32.1% reported 
previously[36]; 18.5% of our rhesus expressed Mamu-A1*001, although the range of 
reported frequency of Mamu-A1*001 expression varies from <1-33% depending on the 
population and country of origin, with Indian-origin rhesus having a much higher Mamu-
A1*001 prevalence compared to Chinese-origin animals.[13, 37, 38] 
We had hypothesized that Mamu-A1*001 in rhesus macaques would demonstrate 
similar neuroprotective effects as has been reported with Mane-A*084:01:01 in pigtailed 
macaques. In this study, expression of the Mamu-A1*001 allele in rhesus was associated 
with a lower plasma viral load, which is consistent with reported findings.[11-13, 39] 
Surprisingly, this difference seen in the periphery did not translate to the CSF, in which 
levels of viral RNA were not different between animals that expressed the allele from 
those that did not. We nonetheless found lower levels of viral RNA and less 
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inflammation in the brains of rhesus expressing Mamu-A1*001, indicating that Mamu-
A1*001 is neuroprotective. This indicates greater MHC class I-mediated viral control in 
the brain compared to the periphery, underscoring the unique nature of T cell-mediated 
immunity in the central nervous system. There was no difference in plasma or CSF viral 
loads of pigtailed macaques that expressed Mane-A*084:01:01. Nonetheless, both SIV 
RNA and inflammation in the brain were lower in pigtailed macaques that express Mane-
A*084:01. 
This study illustrates the marked differences in SIV disease progression that 
genetically distinct species have in response and outcome to an identical neurovirulent 
inoculum. In addition, the lack of appreciable difference in plasma viral loads between 
pigtailed macaques and rhesus macaques at acute infection (d10 p.i. P=0.16, Mann-
Whitney) implies that the intrinsic/innate immune responses are not playing a major role 
in species differences. Rather, adaptive, in particular cell-mediated, immunity is the 
major determinant of species differences in disease outcome to SIV. Clearly, the 
relationship between MHC class I alleles and disease outcome is complex and 
multifactorial, and no single MHC class I allele will define the whole immunologic 
outcome. Thus, deeper and more comprehensive MHC class I haplotyping of these 
animals will be critical to fully understanding the relationship between host genetics and 
viral immunity. This is also an important consideration during vaccine development—
these findings suggest that vaccination against one single epitope is unlikely to be 
completely effective. If we are to understand the differences between individual 
responses to HIV-1 infection, we must try to understand the differences we see in the best 
models available to us, namely, primate models of lentiviral disease. 
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II: Figures 
Pigtailed macaques  Rhesus macaques 









A1P005 46 + -  19K 36 + - T4363 48 + +  20L 47 + - PCf2 50 + -  20E 49 + - 72T 57 + -  110-93 56 + - PYv1 60 + -  21L 84 - + PWe2 60 + -  14K* 85 + - PNl2 62 + -  12L* 85 - - A1P014 66 + -  21M* 86 - - BM03 67 + -  23M* 87 -  18242 72 + -  32M 90 + - CC33 73 + -  P408 119 + - PBm2 77 + +  13H 121 + - 11U 77 + +  S246 122 + - BK09 82 + -  10M 130 -  BI55 82 + -  15M 133 + - PDi2 83 + -  3I 178 + - 01P006 83 + -  12M 214 - - 01P005 83 - +  12H 230 - - T4364 84 - -  P407 238 - + PEi2 84 - -  22K 240 - - PAj2 84 - -  526-91 261 - - BP41 84 + -  257-92 295 - - BP33 84 - +  13U 327 - + A1P003  84 - +  16G 339 - - 03P003 84 + -  451-93 380 - - A1P018 85 - +  332-93 489 - + 02P004 85 - -  AQ04 532 - - 18292 85 + +  24G 554 - - 17850 85 + -  3H 560 - + A2P005 86 + +      A1P016 86 - +      394 86 + -      PSk2 87 - -      18031 87 + -      389 87 + -      PUi2 88 - +      708 88 + -      17834 92 - +      387 92 + -      PJk2 93 - +      713 93 - -      18033 94 + -      715 94 - -      PRk2 98 - +        
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Table 1. MHC I allele genotyping and presence of SIV-associated encephalitis at 
death/euthanasia. A total of 44 pigtailed macaques and 29 rhesus macaques were dual 
inoculated with SIV/B670 and SIV/17E-Fr. The initial three rhesus macaques (*) that 
















































Figure 1. Survival and CD4+ T cell loss in pigtailed macaques and rhesus macaques. 
SIV-inoculated rhesus macaques (red) survived significantly longer than pigtailed 
macaques (blue) (A). After SIV-inoculation, pigtailed macaques (blue) had a greater drop 
in CD4 T cells than rhesus macaques (red) as measured in absolute change from prebleed 





























Figure 2. Comparative viral replication between pigtailed and rhesus macaques in 
plasma, CSF, and tissues. The viral load in both plasma (A) and CSF (B) was higher in 
pigtailed macaques (blue) compared to rhesus macaques (red). By d84 p.i., viral load in 
the plasma (C) and CSF (D) were significantly lower in rhesus macaques compared to 
pigtailed macaques. P values for groupwise comparisons (C,D) were determined using 
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Species SIVE - SIVE + Total 
Pigtailed 16 28 44 
Rhesus 15 11 26 
Totals 31 39 70 
 
 
Table 2. The incidence of SIV-associated encephalitis in pigtailed macaques 
compared to rhesus macaques. Pigtailed macaques are more likely to develop SIV-
associated encephalitis (SIV-E) than rhesus macaques based on histopathologic scoring 






































Figure 3. Longitudinal pro-inflammatory markers in the CSF in pigtailed versus 
rhesus macaques. CSF levels of IL-6 (A) and MCP-1 (CCL2) (B) were higher at acute, 
asymptomatic, and chronic/terminal phases of disease in pigtailed macaques (blue) 
































Figure 4. Comparative terminal tissue viral loads in pigtailed and rhesus macaques. 
Viral load in the spleen (A) and basal ganglia (B) were higher in pigtailed macaques, 
although these differences are not statistically significant. P values for groupwise 
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Rhesus macaques Pigtailed macaques 
Mamu-
A*001 SIVE - SIVE + Total 
Mane-
A1*084:01:01 SIVE - SIVE + Total 
POS 5 0 5 POS 9 5 14 
NEG 9 11 20 NEG 7 23 30 
Total 14 11 25 Total 16 28 44 
 
 
Table 3. The effect of host genetics on development of SIVE in pigtailed and rhesus 
macaques. Both Mane-A1*084:01:01 in pigtailed macaques and Mamu-A*001 in rhesus 
macaques were neuroprotective, in that expression of these alleles was associated with 
failure to develop encephalitis. This association was stronger in pigtailed macaques (P = 
0.0113, one-sided Fisher’s exact) compared to rhesus macaques (P = 0.0377, one-sided 
Fisher’s exact), although expression of the neuroprotective MHC class I alleles 
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Figure 5. The effect of host genetics on plasma, CSF, and brain viral loads in 
pigtailed and rhesus macaques. Terminal viral load levels segregated by MHC class I 
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allele expression were compared in plasma (A), CSF (C), and basal ganglia (E) in 
pigtailed and rhesus macaques (B,D, and F respectively). Although differences in 
terminal plasma and CSF viral loads were variable, immunodominant MHC class I alleles 
in both species were associated with decreased brain viral load. P values for groupwise 
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Introduction: 
Entering the fourth decade of the HIV-1 epidemic, efforts to find an effective 
vaccine strategy continue to be frustrating given mixed results.[1-4] Studies of HIV-
infected individuals categorized as long term nonprogressors and elite controllers have 
shown an overrepresentation of certain major histocompatibility complex (MHC) class I 
alleles, including HLA-B*5701 and HLA-B*27, that suggest cytotoxic T lymphocyte 
(CTL)-mediated MHC class I dependent immunologic pressure is a crucial mechanism 
for HIV control.[5-8] A recent genome-wide association study of HIV progression 
conducted by the International HIV Controllers Society confirmed this by showing that 
over 300 single nucleotide polymorphisms (SNPs) with association to HIV disease 
progression were identified only within the MHC.[9] The discovery of a link between 
expression of certain protective MHC class I alleles and decreased progression to AIDS 
has stressed the importance of understanding host genetics and MHC class I-mediated 
immunologic control of viral replication when considering vaccine design.  
Shortly after HIV-1 was identified as the cause of AIDS, physicians recognized 
that individuals with AIDS frequently demonstrated varying degrees of HIV-associated 
neurocognitive disorders (HAND) that ranged from HIV-associated dementia (HAD) to 
asymptomatic neurocognitive impairment (ANI).[10] With widespread availability of 
effective antiretroviral therapy, the challenges of clinical management of HIV-infected 
individuals have shifted from treating life-threatening opportunistic infections to 
managing a chronic disease in an increasingly aging HIV-infected population. 
Consequently, although the incidence of HAD has decreased with the advent of effective 
ART, the cumulative prevalence of HAND has remained unchanged because of a relative 
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increase in the mild to moderate manifestations.[11] This trend is especially disturbing 
because individuals with HAND overall tend to have worse clinical outcome with higher 
rates of mortality and lower adherence to treatment.[12] 
 Cytotoxic lymphocytes likely play an important role in the pathogenesis of HIV-
associated neurologic disease. Perivascular CD8+ T cells have been demonstrated in the 
brains of patients with HIV-associated encephalitis (HIVE)[13-16], even before the 
development of clinical neurologic signs.[16] In addition, rhesus macaques (Macaca 
mulatta) depleted of CTLs through the use of anti-CD8 monoclonal antibodies and then 
infected with simian immunodeficiency virus (SIV) have an extremely high incidence of 
SIV-associated encephalitis (SIVE).[17-19] 
 Given the importance of CTLs in the pathogenesis of HIV CNS disease, it is 
surprising that so few studies have examined the relationship between protective MHC 
class I allele expression and the development of lentiviral-associated neurologic disease. 
Using a well-characterized accelerated model of SIVE in pigtailed macaques (Macaca 
nemestrina)[20-22], our group has shown that the expression of the MHC class I allele 
Mane-A1*084:01:01 (formerly Mane-A*10) is neuroprotective; animals that lack this 
allele are 2.5 times more likely to develop SIVE and have significant CNS SIV 
replication.[23] Correspondingly, longitudinal CSF and plasma SIV RNA sequencing 
revealed the development of a canonical escape in SIV Gag KP9 (K165R) following the 
emergence of Mane-A1*084:01:01/Gag KP9 tetramer-specific CTLs, demonstrating that 
CTL-mediated immunologic pressure was driving the escape.[24] Also, the SIV Gag 
K165R escape mutation was archived in latent proviral DNA and was present in resting 
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CD4+ T cells, indicating that the escape mutation could persist in latent reservoirs such 
as the brain.[24] 
 In this study, we engineered the Gag K165R point mutation into the neurovirulent 
molecular clone SIV/17E-Fr. Escape mutations in HIV and SIV are typically associated 
with a loss of fitness, and indeed, the development of Gag K165R escape in Mane-
A1*084:01:01-positive pigtailed macaques has been shown by others to be associated 
with decreased plasma viral load.[25] The main goal of this study was to evaluate the 
potential fitness cost of SIV Gag K165R, an escape mutation that develops as the result 
of CTL-mediated immune pressure associated with the known neuroprotective MHC 
class I allele Mane-A1*084:01:01. We show that inoculation of Mane-A1*084:01:01-
positive pigtailed macaques with SIV/17E-Fr K165R resulted in lowered CSF viral loads 
compared to macaques inoculated with wildtype SIV/17E-Fr. Reversion to wildtype SIV 
Gag KP9 in animals inoculated with SIV/17E-Fr K165R also only occurred in the CSF. 
Finally, we utilized a novel VLP-based vaccine platform to induce targeted CTL-
mediated immune pressure on Gag KP9, and found that vaccinated animals challenged 
with wildtype SIV/17E-Fr have a lower viral load in the CSF when compared to 
unvaccinated controls. Plasma viral levels remain unaffected in any of these studies, 
suggesting that Mane-A1*084:01:01-associated CTL control is especially crucial to 




Generation of the escape neurovirulent clone SIV/17E-Fr K165R 
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We constructed an infectious SIV molecular clone containing the K165R escape 
mutation (Figure 1) by designing synthetic oligonucleotides with an A to G point 
mutation to modify the KP9 segment of Gag in the SIV/17E-Fr plasmid to K165R using 
the QuikChange Site-directed Mutagenesis kit (Stratagene, Agilent Technologies©). 
Briefly, the KP9 sequence was excised from pUC19 SIV 17E-Fr and inserted into a 
smaller plasmid, pDSRed N1, for site-directed mutagenesis.  After the sequence was 
confirmed by direct sequencing, the insert was excised with the restriction enzyme Sbf1 
and re-ligated back into the original plasmid. Stocks for in vitro and in vivo experiments 
were generated by transfecting this plasmid into CEMx174 cells. 
 
Primary cell isolation and culture 
Primary pigtailed macaque lymphocytes and macrophages were obtained from 
heparinized peripheral whole blood collected from adult macaques (healthy donors or 
animals in this study). PBMCs were isolated by discontinuous density gradient 
centrifugation with 25% Percoll, and subsequently cultured to select for either 
lymphocytes or macrophages as previously described.[26, 27] Briefly, peripheral blood 
lymphocytes were cultured by stimulating 1 x 107 uninfected PBMC in R10 (RPMI 
supplemented with 10% FBS, gentamicin (50 mg/ml), 2 mM glutamine,10 mM HEPES 
buffer) containing PHA (2µg/mL) and IL-2 (10 U/mL) for 48 hours, then cells were 
washed and resuspended at a concentration of 2 x 106 cells/ml in R10 with IL-2. Primary 
macrophages were cultured in 20% macrophage differentiation media (RPMI 
supplemented with 20% human serum, gentamycin, glutamine, HEPES, and macrophage 
	   79	  
colony stimulating factor [100U]) for 7 days, then washed and resuspended in 10% 
macrophage differentiation media (with 10% human serum). 
Microglia were isolated from macaque cerebral cortex as previously 
described.[28] Briefly, fresh cortical tissue was minced and trypsinized with 0.25% 
trypsin, DNase (50 µg/mL), and gentamycin (50 µg/mL) in DMEM [4.5g/L glucose]). 
Trypsinized tissue was filtered into a clean 50mL conical tube using 183 µM sterile mesh, 
washed, resuspended in sterile PBS, and centrifuged with Percoll for 35 minutes at 
15,000 rpm in an Oakridge tube. The microglia were then removed from beneath the 
myelin layer and filtered through a 40µm mesh. Cells were plated in DMEM with 10% 
FBS in 25-cm2 flasks overnight, washed, and cultured for 5 days in DMEM 
supplemented with 5% FBS, 5% giant-cell-growth-tumor conditioned media (OriGen, 
Gaithersburg, MD), 1mM sodium pyruvate, and 50 µg of gentamicin/mL. 
 
In vitro viral replicative fitness assays 
 Primary macaque cells (lymphocytes, macrophages, and microglia) and 
CEMx175 cells were infected in duplicate with either SIV/17E-Fr (MOI=0.05), SIV/17E-
Fr K165R (MOI=0.05) in 6 well plates or 25-cm2 flasks. After 24 hours, the cells were 
washed three times with PBS to remove virus and then cultured in appropriate media (see 
above) for 15 days. Culture supernatants were subsequently collected at 48-hour intervals 
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A total of 10 male juvenile Mane-A1*084:01:01-positive pigtailed macaques 
(Macaca nemestrina) were used in this study. MHC class I expression by pigtailed 
macaques was evaluated by sequence specific PCR or Roche 454 Titanium 
pyrosequencing.[24] Six macaques were intravenously inoculated with either SIV/17E-Fr 
or SIV/17E-Fr K165R (groups 1 and 2, Table 1) at a dose of AID50 10,000. Two 
additional macaques (group 3, Table 1) were intravenously dual-inoculated with 
intravenously inoculated with SIV/DeltaB670 (50AID50) and SIV/17E-Fr (AID50 
10,000) as previously described.[20] The final two macaques (group 4, Table 1) were 
primed then boosted in approximately two-week intervals with 250 µg KP9-loaded VLP 
administered intradermally then intramuscularly (quadriceps muscle) until a Gag KP9-
specific tetramer response was achieved, than challenged with SIV/17E-Fr (AID50 
10,000). For all animals, blood and CSF samples were taken approximately every 14 
days, and animals were perfused with sterile saline when euthanatized at day 84 post 
inoculation. These studies were approved by the Johns Hopkins University Institutional 
Animal Care and Use Committee. 
 
Quantitation and sequencing of SIV RNA 
 SIV RNA was measured in the plasma and CSF by real-time reverse transcription 
PCR (qRT-PCR) using primers directed against SIV Gag as previously described.[24] 
PCR was performed on cDNA generated from the plasma, CSF, and cultured cell 
supernatant with the SIV Gag KP9-specific primers (forward) 5_-
CACGCAGAAGAGAAAGTGAA-3_ and (reverse) 
5_GTTCCTCGAAT(AG)TC(GT)GAT CC-3_ using Platinum PCR supermix 
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(Invitrogen) and specific cycle conditions (94°C for 2 min; 30 cycles of 94°C for 15 s, 
56°C for 30 s, 72°C for 1 min; and a final extension of 72°C for 8 min). 
PCR product was cloned (TOPO TA) and colonies were selected for sequencing as 
described.[24] Sequences were aligned and analyzed using Geneious 5.0.2 software.  
 
Measuring SIV Gag KP9 specific CD3+/CD8+ T cells 
 Leukocytes in 0.1 mL whole blood were stained with allophycocyanin (APC)-
conjugated Mane-A1*084:01:01/Gag KP9 tetramer at a 1:500 dilution for 30 minutes at 
room temperature in the dark, followed by counterstaining with anti-CD3-PE (BD, Cat 
#552127), anti-CD4-PerCP-Cy™5.5 (BD, Cat # 552838), and anti-CD8-FITC (BD, Cat 
#557085) conjugated antibodies for 30 minutes at room temperature in the dark. 
Erythrocytes were lysed and leukocytes were fixed with 2 mL FACS lysing solution (BD, 
Cat #349202) for 20 minutes at room temperature, washed twice, and resuspended in 0.5 
mL FACS buffer. At least 20,000 CD4 negative, CD3 positive, CD8 positive, tetramer 
positive cells were acquired using an LSRFortessaTM flow cytometer, and analysis was 
performed using FlowJo (Tree Star Inc., Ashland, OR). The percentage of tetramer 
positive CTLs were normalized to uninfected control animals. 
 
Generation of the Gag KP9-specific virus-like particle (VLP) vaccine 
The virus-like particle (VLP)-based vaccine was composed of bovine 
papillomavirus L1 capsid protein that was genetically engineered to contain 8 glutamic 
acids and a cysteine in a surface exposed loop of the protein with Gag KP9 covalently 
linked to the particle.[29] The negatively charged glutamic acids served as docking sites 
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for protein/peptide antigens with an NH2 tag of 8 positively charged arginines and 




 Blood and CSF were collected from two Mane-A1*084:01:01-positive pigtailed 
macaques (group 4) three times at one-week intervals before vaccination (prebleed 
samples). Following the final prebleed sample collection, both macaques were 
intradermally administered with 100 µg (in 0.1 µL buffered saline) SIV Gag KP9-VLP 
and monitored (day 0). Both animals were boosted intradermally on days 14 and 28, but 
due to sample preparation the dose was later determined to be suboptimal. On days 42, 
56, 84, and 98 both animals were subsequently boosted with VLP by both intradermal 
(100 µg) and intramuscular (250 µg in 0.25 µL buffered saline) routes. Blood and CSF 
were collected on days 14, 28, 42, 56, 62, 70, 84, and 98 post VLP prime at day 0. 
Because SIV Gag KP9 specific CTL responses were consistently observed by tetramer 
FACS analysis by this point, VLP boosts were discontinued. Animals were challenged 




Kinetics of viral replication in vitro 
 Replication of wildtype SIV/17E-Fr and mutant SIV/17E-Fr K165R were directly 
compared in vitro in the lymphocyte cell line CEMx174, macaque peripheral blood 
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lymphocytes, macrophages, and microglia (figure 2). The goals of these in vitro studies 
were to 1) confirm that the mutant virus construct SIV/17E-Fr K165R was replication 
competent in vitro, and 2) compare the replicative fitness of SIV/17E-Fr K165R versus 
the wildtype clone SIV/17E-Fr. Previous studies using SHIV strains have shown rapid 
reversion of the Gag K165R mutation to wildtype KP9 when inoculated into animals that 
do not mount an immunologic response against the KP9 epitope, suggesting that K165R 
mutation incurs a fitness cost.[25]  
By infecting the HIV/SIV permissible hybrid B/T cell line CEMx174, we showed 
that the molecular clone SIV/17E-Fr K165R was able to replicate successfully, but 
produced less virus compared to wildtype SIV/17E-Fr (Figure 2a), suggesting decreased 
replicative fitness. Since CEMx174 cells are a transformed cell line, we also extended the 
competition assays in primary macaque cells isolated from blood (lymphocytes and 
macrophages). Since the backbone of the mutant virus is a macrophage-tropic SIV 
clone[27], the Gag escape mutant was expected to have similar macrophage tropism. As 
expected, SIV/17E-Fr K165R was also replication competent in primary lymphocytes 
and macrophages, but similar to the findings in CEMx174 cells, had slower growth 
compared to the parental virus containing wildtype Gag KP9 (Figure 2b,c).  
As a neurovirulent clone, wildtype SIV/17E-Fr also replicates readily in 
microglia.[28] As an in vitro surrogate measure of viral replication in the brain, we 
isolated and infected macaque microglia. Although the viral growth curve of SIV/17E-Fr 
K165R was more similar to wildtype SIV/17E-Fr in infected primary microglia than in 
primary lymphocytes or macrophages, escape virus still demonstrated lower peak virus 
and a slower growth curve (Figure 2d). Lower in vitro viral replication regardless of cell 
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type was consistent with the premise that the Gag K165R mutation incurs a general 
fitness cost. 
 
Kinetics of viral replication in vivo 
 To determine whether fitness cost of the Gag K165R mutation demonstrated in 
vitro was seen in vivo, we inoculated three Mane-A1*084:01:01-positive pigtailed 
macaques with SIV/17E-Fr K165R (group 2) and compared SIV replication with three 
Mane-A1*084:01:01-positive pigtailed macaques inoculated with wildtype SIV/17E-Fr 
(group 1). These studies were terminated at 84 days post inoculation (PI) and longitudinal 
viral loads in the plasma and cerebrospinal fluid (CSF) were compared (Figure 3). 
Longitudinal plasma viral loads in animals inoculated with mutant SIV/17E-Fr K165R 
were nearly identical to those animals inoculated with wildtype SIV/17E-Fr (Figure 3a). 
In contrast, the median CSF viral load of animals inoculated with SIV/17E-Fr/K165R 
was lower than those inoculated with SIV/17E-Fr after acute infection (Figure 3b). These 
findings illustrate that the fitness cost of SIV Gag mutation may selectively alter CNS 
replication without altering SIV replication in the periphery. 
 In addition, we inoculated two pigtailed macaques expressing the MHC class I 
allele Mane-A1*084:01:01 with both the mutant SIV clone 17E-Fr K165R and the 
immunosuppressive swarm SIV/B670 (group 3) to compare directly with the rapid SIV 
CNS model developed at Johns Hopkins University that utilizes dual infection with17E-
Fr and SIV/B670 to induce SIV CNS disease.[20, 22] However, SIV env sequencing 
revealed that the SIV clone 17E-Fr K165R was rapidly overwhelmed by SIV/B670 
strains, minimizing the detectable biologic effect of SIV/17E-Fr K165R (data not shown). 
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Differences in compartmental viral genotype selection 
 Cloning and sequencing of SIV gag in both the peripheral (plasma) and CNS 
(CSF) compartments in animals inoculated with SIV/17E-Fr K165R (group 2) was used 
to track reversion from mutant Gag K165R to wildtype Gag KP9. Since we inoculated 
pigtailed macaques that express Mane-A1*084:01:01 that would mount constant 
immunologic pressure against reversion to Gag KP9, we did not expect to see significant 
reversion to wildtype. Indeed, previous studies that challenged Mane-A1*084:01:01-
positive pigtailed macaques with a natural SIV isolate containing the Gag K165R 
mutation showed maintenance of the escape mutation.[25] As expected, plasma 
genotyping of SIV gag in the three animals inoculated with SIV/17E-Fr K165R showed 
SIV Gag K165R stability up to day 28 post inoculation (figure 4a,b); however, CSF 
genotyping showed consistent reversion to wildtype at the Gag KP9 locus starting as 
early as 7 days post inoculation in both animals genotyped (figure 4c,d). SIV was 
successfully cultured from the microglia of one of these animals showed a similar pattern 
of reversion, with 25% of virus genotyped having reverted to SIV Gag KP9 wildtype 
(data not shown). We were unable to culture virus from the microglia of the remaining 
two animals. 
The development of specific CTL responses against immunologic epitopes in SIV 
Gag and Tat were longitudinally tracked using ELISPOT assays. Although evidence 
suggests that Gag KP9 is the immunodominant epitope recognized by Mane-
A1*084:01:01, we hypothesized that CTL-mediated immunologic pressure could switch 
to an alternate epitope in the absence of Gag KP9 in the inoculum. Indeed, we found a 
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strong IFNγ response to Tat KVA10, an epitope also shown to be restricted by Mane-
A1*084:01:01.[30] Interestingly, one macaque inoculated with only wildtype SIV/17E-Fr 
showed an equally high Tat KVA10 response as those inoculated with SIV/17E-Fr 
K165R (data not shown). This indicated that there is a consistent immunologic response 
to Tat KVA10 in Mane-A1*084:01:01-positive SIV infected animals, implying that Tat 
KVA10 is a codominant epitope whose effect is best seen when the strong Gag KP9 
response disappears. Sequencing of the Tat KVA10 locus in day 14 plasma failed to 
show escape in response to increased Tat epitope CTL-mediated immune pressure (data 
not shown).  
Mutations that develop outside of an immunodominant viral epitope can partially 
restore viral fitness, and are termed compensatory mutations. Mane-A1*084:01:01-
positive pigtailed macaques vaccinated with an SIV/influenza vaccine that rapidly 
developed SIV Gag K165R escape commonly also subsequently developed a Gag V145A 
compensatory mutation.[31] Interestingly, we found no evidence of V145A or other 
compensatory mutations in the region of KP9 in our animals. 
 
Virus-like particle vaccine platform targeting SIV Gag KP9 
 To boost KP9-specific CTL responses before SIV inoculation that specifically 
targets the SIV Gag KP9 epitope and thereby accelerate K165R escape in animals 
inoculated with SIV/17E-Fr, we utilized a unique vaccine platform designed to induce a 
robust CMI response using a virus-like particle that presented the SIV Gag KP9 peptide. 
Two Mane-A1*084:01:01-positive pigtailed macaques were primed and boosted until a 
consistent Gag KP9-specific CTL response was observed. We induced a robust CTL 
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response in both animals, as measured by Gag KP9-tetramer response (Figure 5b). 
Interestingly, intradermal vaccination had minimal ability to prime and boost an immune 
response, while the intramuscular route produced a strong response within two weeks of 
the first boost (day -42 pre-inoculation, Figure 5b). 
After establishing that VLP vaccination increases Gag KP9-specific immunologic 
response, animals were challenged with a single-inoculum of wildtype SIV/17E-Fr. Post-
challenge, both animals responded with an early and  robust KP9 tetramer-specific 
anamnestic response in acute infection (Figure 5b), considerably earlier than typically 
seen in unvaccinated animals at day 56 p.i. (Figure 5a). While VLP vaccination did not 
measurably alter plasma viral load, both animals had lower viral loads in the CSF 




 For the first time, this study has demonstrated a uniquely CNS compartment-
specific fitness cost to viral escape from MHC class I-mediated immunologic pressure. 
After inserting the canonical SIV Gag escape mutation K165R into the neurovirulent 
molecular clone SIV/17E-Fr, we were inoculated Mane-A1*084:01:01-positive pigtailed 
macaques with the cloned escape mutant virus and demonstrated decreased viral load in 
the CSF, but not the plasma. Viral sequencing in these animals revealed reversion to 
wildtype Gag KP9 only in the CSF and not the plasma, corresponding with decreased 
CNS fitness of K165R. In a reciprocal experiment we induced targeted immunologic 
pressure by vaccinating animals with a novel VLP-based construct that focused the CTL 
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response on Gag KP9. Subsequent challenge with wildtype SIV/17E-Fr resulted in a 
decreased viral load in the CSF, but not plasma. Together, these findings provide 
compelling evidence that suggest a CNS-specific loss in viral fitness that is incurred as a 
result of Gag escape. 
VLP Gag KP9 vaccination provided us with a novel way to induce targeted CTL-
specific immunologic pressure. VLP particles are especially immunogenic because of 
their size (40-50 nm), repetitive surface docking sites that present foreign antigen, and 
their ability to self-adjuvanate.[29, 32-34] VLP vaccine prime and boosts delivered 
intramuscularly induced a robust KP9-specific CTL response as measured both by the 
number of Mane-A1*084:01:01/KP9 tetramer positive CTLs as well as CTL production 
of IFNγ and TNFα as measured by intracellular staining FACS (data not shown). 
Memory phenotype FACS analysis of tetramer positive CTLs also showed that almost all 
of the KP9 specific memory CD8+ T cell response consisted of effector memory cells, 
with 42% of tetramer positive cells defined as EM1 transitional memory cells 
(CD95+/CD28+/CCR7-), 55% defined as EM2 fully differentiated effector memory 
(CD95+/CD28-/CCR7-), and only the remaining 3% as central memory 
(CD95+/CD28+/CCR7+). In rhesus macaques, vaccines that are able induce robust 
effector memory T cell responses are believed to provide better protection against SIV 
infection than vaccines that produce predominantly central memory T cell responses 
(lymphoid tissue-based) because of the amount of time necessary for an effective antigen-
stimulated response to mount.[35-37] In the future, it would be useful to carry out a 
similar study with VLP vaccinated pigtailed macaques to evaluate how long the Gag KP9 
T cell memory response persists. As a single-epitope vaccine is not likely to effectively 
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prevent SIV or HIV infection due to the development of escape and/or compensatory 
mutations, further studies vaccinating with multiple SIV Gag epitopes on a VLP 
backbone are needed. 
Evaluation of CD8+ T cell functional responses to Gag peptide pools by Smith et 
al (2005) first recognized Gag KP9 as an important immunodominant SIV Gag epitope in 
pigtailed macaques.[38] This is especially relevant because KP9 is a homologue of the 
Gag epitope KF11, which is recognized by HLA-B57*01.[39] Identification of alleles 
that were shared amongst animals that responded to Gag KP9 and functional studies to 
demonstrate binding confirmed that Mane-A1*084:01:01 was the main SIV Gag KP9 
presenting molecule.[38] Furthermore, SIV in Mane-A1*084:01:01-positive animals 
rapidly developed the canonical escape mutation Gag K165R, and these animals had 
lower levels of SIV RNA in the plasma, suggesting a replicative fitness cost to 
mutation.[38, 40] When Mane-A1*084:01:01-negative macaques were inoculated with 
SHIV containing the Gag K165R mutation, there was rapid reversion to wildtype KP9, 
confirming the fitness cost to mutation.[41]  
In direct contrast to these findings, our lab found no difference in either plasma 
viral RNA or CD4+ cell counts between pigtailed macaques that expressed Mane-
A1*084:01:01 and those that did not; however, CSF viral RNA was lower in Mane-
A1*084:01:01-positive macaques.[23] The main difference between these groups was 
inoculum: the animals reported on by Smith et al were inoculated with SIVmac251 while 
our animals were dual-inoculated with SIV/DeltaB670 and SIV/17E-Fr in order to 
maximize the development of SIVE. Data from this study were more consistent with data 
from our dual-inoculated animals than animals inoculated with SIVmac251. Animals in 
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this study were all Mane-A1*084:01:01-positive and were inoculated with either the 
wildtype SIV/17E-Fr or escape neurovirulent clone SIV/17E-Fr K165R, and the only 
difference between the two groups was in CNS viral RNA. These data support the view 
that the efficacy of antigen-specific CTL control in the CNS clearly differs from the 
periphery.[42] 
Numerous studies in both HIV[43-46] and SIV[31, 47-50] have reported the 
emergence of compensatory mutations, or mutations that occur outside of an epitope that 
may partially or completely restore viral replicative fitness. In rhesus macaques that 
express the MHC class I allele Mamu-A1*001, a variety of compensatory mutations 
emerge concurrent with the development of escape at the Mamu-A1*001-restricted Gag 
epitope CM9 (T182A).[47, 50] In several studies, compensatory mutations in SIV have 
been shown to restore viral replicative capacity specifically by restoring normal viral 
packing and assembly.[49, 51] Likewise, pigtailed macaques that express Mane-
A1*084:01:01 will often develop a second Gag mutation after escape from Gag KP9 has 
occurred 20 amino acids upstream (V145A).[31] Interestingly, we found no evidence of 
compensatory mutations in our Mane-A1*084:01:01-postivie pigtailed macaques, either 
at V145A or new sites; however, sequences in our study only spanned several hundreds 
of amino acids before and after Gag KP9, so it is entirely possible that compensatory 
mutations may have occurred at other regions more distant in Gag. 
In addition to SIV Gag SIV, Mane-A1*084:01:01 recognizes two 
immunodominant epitopes in SIV Tat: KVA10 (KKETVEKAVA) and KSA10 
(KKAKANTSSA).[30] Escape mutations also develop in both Tat epitopes, although 
there is not a single consensus escape mutation that emerges unlike canonical KP9 
	   91	  
escape.[30] We hypothesized that the Mane-A1*084:01:01-mediated CTL control would 
switch in focus from Gag KP9 to one or both of these Tat epitopes animals that were 
inoculated with SIV/17E-Fr K165R. We found that these animals had a robust early 
response to Tat KVA10 but not Tat KSA10 (as measured longitudinal by IFNγ ELISPOT 
and KVA10 or KSA10 tetramer response). At no point in the 84 day study did any 
animals inoculated with SIV/17E-Fr K165R show a CTL response to Gag KP9. 
Interestingly, we found an equal response to Tat KVA10 68X (one of the animals 
inoculated with SIV/17E-Fr), suggesting that, rather than an immunologic switch to Tat 
KVA10 in the absence of Gag KP9, these animals responded to Tat KVA10 as a 
codominant epitope. 
There are several limitations to a study of this nature. We were limited in sample 
size given limited availability of macaques. Single-inoculation using only SIV/17E-Fr 
doesn’t reliably cause overt encephalitis, although there is evidence of productive 
infection in the CNS. None of the animals in this study developed SIVE. Dual-
inoculation with SIV/DeltaB670 would be the most ideal way to evaluate CNS 
pathology; however, we found that the immunosuppressive swarm SIV/DeltaB670 
quickly overwhelmed SIV/17E-Fr K165R replication in the brain, making the pathologic 
effects of our introduction of the Gag K165R mutation in SIV/17E-Fr difficult to 
evaluate. Since SIV/DeltaB670 is a swarm and not a cloned virus, it was impossible to 
introduce the Gag K165R mutation into all variants present in the DeltaB670 inoculum.  
SIV env cloning and sequencing allows us to differentiate between the 
immunosuppressive swarm and the neurovirulent clone, SIV/17E-Fr. Interestingly viral 
RNA was 100% SIV/DeltaB670 in the basal ganglia; however, one of the two animals 
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was 100% SIV/17E-Fr when SIV DNA was sequenced, implying that only the 
neurovirulent clone SIV/17E-Fr was able to integrate. Full viral genome sequencing 
would be necessary to rule out the possibility of viral recombination between SIV/Delta 
B670 and SIV/17E-Fr.  
Surprisingly, few studies of HIV or SIV have specifically looked at the 
association of MHC class I-mediated viral control and CNS outcome.[23, 24] We have 
found compelling evidence for epitope-specific targeted immune pressure on viral fitness 
that is CNS-specific. In addition, we developed a vaccine strategy to target CTL-
mediated immunologic pressure on this Gag epitope and found subsequent decreased SIV 
viral load in CNS. As the struggle to find an effective vaccine strategy for HIV-1 
continues, it is extremely important to understand the interactions between host 
immunogenetics and organ specific HIV-induced disease. Our data provide the rationale 
for the development of a therapeutic vaccine-approach to control HIV-associated system-
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Fig 1. The MHC class I allele Mane-A1*08401 recognizes KP9, a dominant epitope 
in SIV Gag. 
In response to MHC class I-mediated CTL pressure, Mane-A1*08401 positive macaques 
develop a consensus escape mutation in the capsid region of SIV Gag, identified as 
K165R escape SIV, as the result of a single point mutation lysine to arginine at amino 
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Group Number of animals 
Inoculum 
VLP vaccinated 
SIV/17E-Fr SIV/17E-Fr K165R 
SIV/Delta
B670 
1 3 + - - - 
2 3 - + - - 
3 2 - + + - 
4 2 + - - + 
 
 
Table 1. Animal groups in this study. Ten pigtailed macaques were inoculated with 











































Fig 2. Comparative replication of SIV/17E-Fr K165R vs wildtype SIV/17E-Fr. In 
vitro, replication of SIV/17E-Fr K165R (red) was lower than wildtype SIV/17E-Fr (blue) 
in the CEMx174 B/T cell hybrid line (A) and in cultured primary lymphocytes (B), 



















Fig 3. Replicative fitness of SIV/17E-Fr versus SIV/17E-Fr/K165R in Mane-
A1*08401 positive macaques. Viral load in the plasma (A) was similar in Mane-
A1*08401 positive pigtailed macaques infected with SIV/17E-Fr (blue) and SIV/17E-Fr 
K165R (red). In contrast, CSF viral load in macaques infected with SIV/17E-Fr/K165R 
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Fig 4. Longitudinal SIV RNA genotyping in the plasma and CSF of two pigtailed 
macaques inoculated with SIV/17E-Fr K165R. 
In macaques inoculated with the cloned escape virus, SIV/17E-Fr K165R, reversion to 
wildtype SIV Gag KP9 (blue) developed rapidly in the CSF but not the plasma. Viral 
RNA was isolated from CSF and plasma and viral genotype was established by cloning 



















Fig 5. Impact of Gag KP9 vaccination on SIV replication after SIV/17E-Fr 
challenge. The SIV Gag KP9-specific CTL response in an unvaccinated animal (a) 
inoculated with SIV/17E-Fr (blue) peaked at day 56 p.i., while animals inoculated with 
SIV/17E-Fr K165R (red) had no significant KP9 CTL response (n=3, median). In 
contrast, peak KP9 CTL response in VLP vaccinated animals (purple [22Y] and green 
[74X] lines) (b) occurred at days 14 and 21 p.i., much earlier than the unvaccinated 
animals. Plasma viral loads (c) in VLP vaccinated animals (purple and green) challenged 
with SIV/17E-Fr were similar to the plasma viral load of unvaccinated animals (blue) 
inoculated with SIV/17E-Fr (n=3, median). However, the CSF viral loads of VLP 
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vaccinated animals (purple and green) were lower than wildtype controls (blue) after 
acute infection by greater than one log. CTL response was measured by percentage of 
CD3+/CD8+/KP9-Mane-A1*08401 tetramer + lymphocytes. Plasma and CSF viral loads 
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Despite encouraging scientific progress made in the last three decades of the 
HIV/AIDS epidemic in understanding HIV immunity and pathogenesis, clinical vaccine 
trials have met with mixed success and an effective prophylactic or therapeutic vaccine 
remains elusive.[1-3] Studies of HIV-infected individuals resistant to AIDS progression, 
such as long-term nonprogressors and elite controllers, have provided compelling 
evidence for the importance of host genetics and the influences of MHC class I on host 
immunity against viral infections.[4-6] Because of remarkable similarities between SIV 
pathogenesis in Asian-origin macaques and HIV pathogenesis in people, nonhuman 
primates have become a popular animal to model HIV/AIDS pathogenesis. In addition, 
nonhuman primate animal models are optimal for studying natural host viral immunity 
because, like humans, macaques have an extremely high diversity of MHC class I allele 
expression.[7-9] 
Macaques have also become an invaluable resource as a model for stuying the 
pathogenesis and treatment of neuroAIDS. Varying degrees and manifestations of HIV-
associated neurocognitive disorders (HAND) are common and debilitating sequela to 
HIV infection. Although the incidence of the most severe form of neuroAIDS, HIV-
associated dementia, has drastically decreased with the advent of effective antiretroviral 
therapy, the overall prevalence of neurologic dysfunction has remained unchanged due to 
an increase in the milder forms of HAND.[10] As the brain is a relatively inaccessible 
organ to study viral disease pathogenesis, animal models have been crucial to studying 
HIV-associated brain pathology.  
Despite the known importance of host genetics on HIV progression, few have 
specifically looked at the relationship between host genetics and the development of HIV 
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associated neurologic disease in great detail.[11] In the series of studies described in this 
thesis, we compared and contrasted species-specific responses to SIV infection as well as 
characterized the dramatic effects that Gag specific MHC class I-mediated immunologic 
pressure has on CNS outcome. In the largest study of its kind, we first compared SIV 
neuropathogenesis and outcome in 44 pigtailed macaques versus 28 rhesus macaques that 
were all dual-inoculated with a neurovirulent clone (SIV/17E-Fr) and an 
immunosuppressive viral swarm (SIV/DeltaB670). Compared to pigtailed macaques, 
rhesus macaques have a markedly prolonged course of disease progression with less 
immunosuppression (lower drop in CD4+ T cells), lower viral loads, and decreased 
progression to SIV-encephalitis (SIVE). For the first time, we also compared head-to-
head the effects that MHC class I allele expression has on the development of neuroAIDS 
in both pigtailed macaques and rhesus macaques, and found that, although there were no 
differences on CSF viral loads based on MHC class I allele expression, both pigtailed and 
rhesus macaques that expressed their respective MHC class I alleles had decreased viral 
loads in the brain. 
In the next series of studies, we characterized the effect of SIV Gag KP9 escape 
(K165R) from the MHC class I allele in pigtailed macaqeus, Mane-A*084:01:01 on viral 
fitness. As we had hypothesized, the Gag escape virus SIV/17E-Fr K165R had lower 
replication in vitro, implying that the K165R mutation incurred a fitness cost. However, 
this fitness cost translated only to reduced viral fitness in the central nervous system when 
we compared pigtailed macaques that were inoculated with wildtype SIV/17E-Fr with 
macaques inoculated with escape SIV/17E-Fr K165R. Viral loads in the CSF were lower 
in animals inoculated with SIV/17E-Fr K165R while viral loads in the plasma remained 
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unchanged compared with wildtype Gag KP9. A surprising finding was that reversion to 
wildtype Gag KP9 occurred only in the CSF and not the plasma. We then stimulated Gag 
KP9 epitope-specific immunologic pressure by vaccinating additional pigtailed macaques 
with a VLP vaccine loaded with Gag KP9, followed by challenge with SIV/17E-Fr. 
Again, vaccinated animals had lower viral loads in the CSF but not the plasma. These 
data show that Gag KP9 mutation in the neurovirulent clone SIV.17E-Fr imparts a 
dramatic fitness cost only in the CNS, suggesting that Gag KP9 may play a crucial role in 
SIV neuropathogenesis. 
Although these studies of MHC class I-mediated effects on the development of 
SIVE have added to the large body of compelling evidence that host genetics play a vital 
role in HIV pathogenesis, MHC allele expression represents only one piece of this 
picture. In addition, we are interested in investigating the importance of T cell receptor 
(TCR) selection as it pertains to viral immunity. The effectiveness of CTL-mediated 
immunity is dependent on a highly diverse array of TCR sequences (clonotypes) that can 
recognize an almost limitless variety of antigens presented on diverse MHC molecules. It 
then stands to reason that it would be almost impossible for TCR clonotypes to be shared 
between individuals; however, several of these “public” clonotype responses have been 
demonstrated in a variety of infectious diseases, including HIV.[12-14] Although TCR 
diversity would be advantageous because of an increased capacity to respond to viral 
epitope mutations, an effective CTL response remains dependent upon TCR binding and 
specificity. The TCR of most T cells comprises two chains, α and β, each of which has 
three complementarity determining regions (CDRs), of which CDR3 is in direct contact 
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with the peptide.[15] Sequencing of the CDR3 regions of TCRs from epitope-specific 
CTLs allows us to evaluate the breadth of TCR clonotypes that respond to that antigen.  
Theoretically, multiple TCR clonotypes targeting the same immunodominant 
epitope might prevent widespread viral escape.[16] Studies of TCR clonotypes that 
respond to immunodominant HIV Gag epitopes have shown evidence of multiple 
clonotypes that expand during the course of infection as well as the emergence of Gag-
specific clonotypes that exhibit cross-reactivity.[16, 17] TCR clonotype sequencing of 
Mane-A*084:01:01-positive macaques that were vaccinated with vaccines expressing 
wildtype SIV Gag KP9 then challenged with SIVmac251 or SHIV showed a widely 
diverse population of TCR clonotypes in SIV Gag KP9-specific T cells.[18] In addition, 
the vast majority of KP9-specific CTL TCR clonotypes identified after vaccination 
subsequently disappeared after SIV challenge.[18] Conversely, rhesus macaques were 
reported to develop a clonal CTL response to vaccine that not only persisted after SHIV 
challenge but was maintained for several years.[19] 
To investigate serial TCR clonotype selection in our SIV model, we isolated 
mRNA from SIV Gag KP9-specific CTLs from a Mane-A*084:01:01-positive pigtailed 
macaque (68X) that was inoculated with wildtype SIV/17E-Fr by FACS sorting 10,000 to 
30,000 CD3 and KP9-tetramer dual-positive lymphocytes using blood samples obtained 
at multiple time points. cDNA synthesis was performed with the 5’ SMARTer RACE 
(rapid amplification of cDNA ends) cDNA amplification kit (Clontech) and anchored 
PCR for TCR β chain (TRB) gene products was performed using the previously described 
protocol and primer sequences.[18] Traditional cloning and sequencing of the amplified 
TRB gene products was performed, and the CDR3 amino acid sequences were identified 
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by the ends of the Vβ regions (identifiable by the amino acid sequence CASS) and the Jβ 
regions (identified by XFGXG). 
To test this technique, we first processed pre-inoculation lymphocytes for TCR 
clonotype sequences and found that we were able to successfully sequence and identify 
CDR3 sequences. We identified a very diverse array of TCR clonotypes with very little 
repeat in clone sequences (Figure 1), which was unsurprising given the lack in selective 
immunologic pressure. Interestingly, at 84 days post-inoculation (terminal bleed), Gag 
KP9 specific CTLs showed marked clonotype selection (Figure 2). We only identified 
three unique TRB CTR3 sequences, and of these, two dominated the immune response. 
This is in contrast to the findings of Smith et al, in which no dominant clonotypes 
emerged at any point post-vaccination or post-challenge. However, this is only one 
animal, and we now are currently genotyping TCR clones at intermediate time points. In 
addition, we have sorted Gag KP9-specific CTLs longitudinally from the two pigtailed 
macaques that were VLP-KP9 vaccinated and challenged with SIV/17E-Fr, which will 
enable us to compare the clonally expanded CTLs post-vaccination with those that 
expanded post-challenge. 
Another aspect of host adaptive immunity that has been gaining interest in recent 
years is the potential utility of antibody-dependent cellular cytotoxicity (ADCC) 
stimulation of natural killer (NK) cells for therapeutic or prophylactic vaccination 
development.[20, 21] ADCC is a unique immunologic process that involves parts of both 
the humoral and cell-mediated immune systems by targeting virus-infected cells whose 
surface antigens have been bound by antibodies that are recognized by Fc receptors 
(CD16) expressed on the surface of NK cells, macrophages, and other immune cells. 
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Classic ADCC involves NK cell activation and subsequent killing of the virus-infected 
cell. The failure of strictly humoral or cell-mediated HIV vaccines to effectively prevent 
HIV infection has led many to believe that the most effective approach to vaccine design 
may be creating a vaccine that stimulates both arms of the immune system.[21] Indeed, 
the presence of ADCC antibodies directed against HIV proteins, especially Env, are 
associated with slower decline of CD4+ T cells and in slower disease progression.[22, 
23]  
To confirm the development of ADCC responses by NK cells in our SIV-infected 
pigtailed macaque model, we measured intracellular cytokine production by macaque NK 
cells that were stimulated with SIVmac239 Env peptide pools (NIH AIDS reagent 
program catalog #2322) using previously reported methods.[24] Peripheral blood 
mononuclear cells were isolated from an uninfected pigtailed macaque and incubated 
with sera from a chronically infected macaque and SIV Env peptide pools. We measured 
intracellular IFNγ and TNFα production by CD3-/CD8+/CD159a+ NK cells and found 
variable IFN-γ and TNF-α production in response to stimulation by multiple SIV Env 
pools (Figure 3). Although this data is preliminary, we believe that these data suggest that 
SIV infection in our pigtailed macaque model induces ADCC responses. Ultimately, the 
goal is to map ADCC response of pigtailed macaques to SIV peptides, not only in Env, 
but of other SIV proteins as well, with the end goal of developing an ADCC-based 
vaccine using the VLP platform. 
Overall, these studies provide compelling evidence that immunologic pressure on 
a highly conserved epitope in Gag drives viral escape that has a detrimental effect on 
viral replication specifically in the CNS, implying CTL-mediated immunity is unique in 
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the CNS when compared to the periphery. As vaccination strategies to enhance CTL 
responses against HIV Gag could promote HIV escape, it is imperative that we fully 
understand the ramifications that therapeutic vaccination could have in the CNS 
including development of neuroAIDS. Hopefully, our studies have helped improve our 
understanding of the interplay of host genetics and CTL-mediated viral immunity on the 
development of SIV-associated neurologic disease with the ultimate goal of developing 
novel immunomodulatory therapies that could protect the CNS from HIV infection.   
















	   115	  
References: 
1.	   Flynn,	  N.M.,	  et	  al.,	  Placebo-­‐controlled	  phase	  3	  trial	  of	  a	  recombinant	  
glycoprotein	  120	  vaccine	  to	  prevent	  HIV-­‐1	  infection.	  J	  Infect	  Dis,	  2005.	  191(5):	  
p.	  654-­‐65.	  
2.	   Buchbinder,	  S.P.,	  et	  al.,	  Efficacy	  assessment	  of	  a	  cell-­‐mediated	  immunity	  HIV-­‐1	  
vaccine	  (the	  Step	  Study):	  a	  double-­‐blind,	  randomised,	  placebo-­‐controlled,	  test-­‐
of-­‐concept	  trial.	  Lancet,	  2008.	  372(9653):	  p.	  1881-­‐93.	  
3.	   Rerks-­‐Ngarm,	  S.,	  et	  al.,	  Vaccination	  with	  ALVAC	  and	  AIDSVAX	  to	  prevent	  HIV-­‐1	  
infection	  in	  Thailand.	  N	  Engl	  J	  Med,	  2009.	  361(23):	  p.	  2209-­‐20.	  
4.	   Migueles,	  S.A.,	  et	  al.,	  HLA	  B*5701	  is	  highly	  associated	  with	  restriction	  of	  virus	  
replication	  in	  a	  subgroup	  of	  HIV-­‐infected	  long	  term	  nonprogressors.	  Proc	  Natl	  
Acad	  Sci	  U	  S	  A,	  2000.	  97(6):	  p.	  2709-­‐14.	  
5.	   Limou,	  S.	  and	  J.F.	  Zagury,	  Immunogenetics:	  Genome-­‐Wide	  Association	  of	  Non-­‐
Progressive	  HIV	  and	  Viral	  Load	  Control:	  HLA	  Genes	  and	  Beyond.	  Front	  
Immunol,	  2013.	  4:	  p.	  118.	  
6.	   Pereyra,	  F.,	  et	  al.,	  The	  major	  genetic	  determinants	  of	  HIV-­‐1	  control	  affect	  HLA	  
class	  I	  peptide	  presentation.	  Science,	  2010.	  330(6010):	  p.	  1551-­‐7.	  
7.	   Pratt,	  B.F.,	  et	  al.,	  MHC	  class	  I	  allele	  frequencies	  in	  pigtail	  macaques	  of	  diverse	  
origin.	  Immunogenetics,	  2006.	  58(12):	  p.	  995-­‐1001.	  
8.	   Karl,	  J.A.,	  et	  al.,	  Major	  histocompatibility	  complex	  class	  I	  haplotype	  diversity	  in	  
Chinese	  rhesus	  macaques.	  G3	  (Bethesda),	  2013.	  3(7):	  p.	  1195-­‐201.	  
9.	   Saito,	  Y.,	  et	  al.,	  Diversity	  of	  MHC	  class	  I	  haplotypes	  in	  cynomolgus	  macaques.	  
Immunogenetics,	  2012.	  64(2):	  p.	  131-­‐41.	  
	   116	  
10.	   Heaton,	  R.K.,	  et	  al.,	  HIV-­‐associated	  neurocognitive	  disorders	  persist	  in	  the	  era	  
of	  potent	  antiretroviral	  therapy:	  CHARTER	  Study.	  Neurology,	  2010.	  75(23):	  p.	  
2087-­‐96.	  
11.	   Mankowski,	  J.L.,	  et	  al.,	  Natural	  host	  genetic	  resistance	  to	  lentiviral	  CNS	  disease:	  
a	  neuroprotective	  MHC	  class	  I	  allele	  in	  SIV-­‐infected	  macaques.	  PLoS	  One,	  2008.	  
3(11):	  p.	  e3603.	  
12.	   Li,	  H.,	  et	  al.,	  Determinants	  of	  public	  T	  cell	  responses.	  Cell	  Res,	  2012.	  22(1):	  p.	  
33-­‐42.	  
13.	   Gillespie,	  G.M.,	  et	  al.,	  Strong	  TCR	  conservation	  and	  altered	  T	  cell	  cross-­‐
reactivity	  characterize	  a	  B*57-­‐restricted	  immune	  response	  in	  HIV-­‐1	  infection.	  J	  
Immunol,	  2006.	  177(6):	  p.	  3893-­‐902.	  
14.	   Yu,	  X.G.,	  et	  al.,	  Mutually	  exclusive	  T-­‐cell	  receptor	  induction	  and	  differential	  
susceptibility	  to	  human	  immunodeficiency	  virus	  type	  1	  mutational	  escape	  
associated	  with	  a	  two-­‐amino-­‐acid	  difference	  between	  HLA	  class	  I	  subtypes.	  J	  
Virol,	  2007.	  81(4):	  p.	  1619-­‐31.	  
15.	   Garcia,	  K.C.	  and	  E.J.	  Adams,	  How	  the	  T	  cell	  receptor	  sees	  antigen-­‐-­‐a	  structural	  
view.	  Cell,	  2005.	  122(3):	  p.	  333-­‐6.	  
16.	   Douek,	  D.C.,	  et	  al.,	  A	  novel	  approach	  to	  the	  analysis	  of	  specificity,	  clonality,	  and	  
frequency	  of	  HIV-­‐specific	  T	  cell	  responses	  reveals	  a	  potential	  mechanism	  for	  
control	  of	  viral	  escape.	  J	  Immunol,	  2002.	  168(6):	  p.	  3099-­‐104.	  
17.	   van	  Bockel,	  D.J.,	  et	  al.,	  Persistent	  survival	  of	  prevalent	  clonotypes	  within	  an	  
immunodominant	  HIV	  gag-­‐specific	  CD8+	  T	  cell	  response.	  J	  Immunol,	  2011.	  
186(1):	  p.	  359-­‐71.	  
	   117	  
18.	   Smith,	  M.Z.,	  et	  al.,	  Limited	  maintenance	  of	  vaccine-­‐induced	  simian	  
immunodeficiency	  virus-­‐specific	  CD8	  T-­‐cell	  receptor	  clonotypes	  after	  virus	  
challenge.	  J	  Virol,	  2008.	  82(15):	  p.	  7357-­‐68.	  
19.	   Sen,	  P.,	  et	  al.,	  Clonal	  focusing	  of	  epitope-­‐specific	  CD8+	  T	  lymphocytes	  in	  rhesus	  
monkeys	  following	  vaccination	  and	  simian-­‐human	  immunodeficiency	  virus	  
challenge.	  J	  Virol,	  2008.	  82(2):	  p.	  805-­‐16.	  
20.	   Madhavi,	  V.,	  S.J.	  Kent,	  and	  I.	  Stratov,	  HIV-­‐specific	  antibody-­‐dependent	  cellular	  
cytotoxicity:	  a	  novel	  vaccine	  modality.	  Expert	  Rev	  Clin	  Immunol,	  2012.	  8(8):	  p.	  
767-­‐74.	  
21.	   Wren,	  L.	  and	  S.J.	  Kent,	  HIV	  Vaccine	  efficacy	  trial:	  glimmers	  of	  hope	  and	  the	  
potential	  role	  of	  antibody-­‐dependent	  cellular	  cytotoxicity.	  Hum	  Vaccin,	  2011.	  
7(4):	  p.	  466-­‐73.	  
22.	   Wren,	  L.H.,	  et	  al.,	  Specific	  antibody-­‐dependent	  cellular	  cytotoxicity	  responses	  
associated	  with	  slow	  progression	  of	  HIV	  infection.	  Immunology,	  2013.	  138(2):	  
p.	  116-­‐23.	  
23.	   Chung,	  A.W.,	  et	  al.,	  Activation	  of	  NK	  cells	  by	  ADCC	  antibodies	  and	  HIV	  disease	  
progression.	  J	  Acquir	  Immune	  Defic	  Syndr,	  2011.	  58(2):	  p.	  127-­‐31.	  
24.	   Chung,	  A.W.,	  et	  al.,	  Rapid	  degranulation	  of	  NK	  cells	  following	  activation	  by	  HIV-­‐












Length	   CDR3	   Jβ	   #	   %	  
14	   CASSQDRASTDPQY	   FGPG	   1	   2.1	  
11	   CSATTSGNTVY	   FGEG	   1	   2.1	  
13	   CSARDQGRNSLPH	   FGNG	   1	   2.1	  
12	   CSVGDRGNDYT	   FGSG	   1	   2.1	  
7	   CASSPGVGPEQY	   FGPG	   1	   2.1	  
13	   CSADPWTPNQPQY	   FGDG	   1	   2.1	  
11	   CASVETYGEQF	   FGPG	   1	   2.1	  
14	   CASSHLQGANYDYT	   FGSG	   1	   2.1	  
13	   CASSQWDRVNEQY	   FGPG	   1	   2.1	  
14	   CASGKQGGMNTEAF	   FGQG	   1	   2.1	  
14	   CASSEETDSNQPQY	   FGDG	   1	   2.1	  
14	   CATSEDGQGNYDYT	   FGSG	   1	   2.1	  
16	  
CASSRDGLMGLNEKL
F	   FGSG	   1	   2.1	  
13	   CASSQAGGAYEQY	   FGPG	   2	   4.3	  
14	  
CSADVWMGTYGEQ
F	   FGPG	   1	   2.1	  
13	   CASSLELRGQPQY	   FGDG	   1	   2.1	  
13	   CASSLGWGEGEQF	   FGPG	   1	   2.1	  
13	   CASSHPQGGEKLF	   FGSG	   2	   4.3	  
13	   CATSDLQGGDDYT	   FGSG	   1	   2.1	  
17	  
CASSWREAISASQNT
QY	   FGAG	   1	   2.1	  
14	   CASSDLQDPRTEAF	   FGQG	   1	   2.1	  
13	   CATSDNGSNEKLF	   FGSG	   1	   2.1	  
12	   CASSSTVTDPQY	   FGPG	   1	   2.1	  
20	  
CASSPLDRAMGGDR
QNTQY	   FGAG	   1	   2.1	  
14	   CATSETDRLDQPQY	   FGDG	   1	   2.1	  
13	   CASSAGANTAQLF	   FGEG	   1	   2.1	  
14	   CATSESGQLTDPQY	   FGPG	   1	   2.1	  
13	   CSAGGQGLLGEQF	   FGPG	   1	   2.1	  
14	   CASSGGQGLLGEQF	   FGQG	   1	   2.1	  
14	   CATSDLPDSVYDYT	   FGSG	   1	   2.1	  
17	  
CASSQDLGGTAGAS
VLT	   FGAG	   1	   2.1	  
15	   CASSPSIRQGTYEQY	   FGPG	   1	   2.1	  
13	   CASSQGWGSHDYT	   FGSG	   1	   2.1	  
13	   CASSTRQGDSPLH	   FGNG	   3	   6.4	  
14	   CASSSAAKAGNTVY	   FGEG	   1	   2.1	  
13	   CASGFGTGTDPQY	   FGPG	   1	   2.1	  
14	   CASSPVRDSPAQLF	   FGEG	   1	   2.1	  
12	   CASSETGGHTQY	   FGAG	   1	   2.1	  
B.	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15	  
CASRRDWGSSADPQ
Y	   FGPG	   1	   2.1	  
15	   CASSESRAASTAQLF	   FGEG	   1	   2.1	  
14	   CASSLDSLWNQPQY	   FGDG	   1	   2.1	  
14	   CASSISQGGVQPQY	   FGDG	   1	   2.1	  
17	  
CSVGTNGQGGNSGN
TVY	   FGEG	   1	   2.1	  
	  
 
Figure 1. Preliminary TCR sequencing of lymphocytes from a Mane-A*084:01:01-
positive pigtailed macaque confirmed our technical ability to sequence TCR clonotypes. 


































	   120	  
A.	  
Length CDR3 Jβ # % 
12 CASSTGSYQPQY FGDG 1 4.8 
12 CASSSPVLHDYT FGSG 12 57.1 





Figure	  2.	  Development	  of	  epitope-­‐specific	  TCR	  selection	  in	  an	  SIV	  infected	  
pigtailed	  macaque.	  CRD3	  TCR	  sequencing	  of	  SIV	  Gag	  KP9-­‐specific	  CTLs	  in	  a	  Mane-
A*084:01:01-positive pigtailed macaque inoculated with SIV/17E-Fr showed clear TCR 
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Figure	  3.	  ADCC	  response	  in	  pigtailed	  macaques.	  Stimulation	  of	  naïve	  macaque	  
natural	  killer	  cells	  with	  serum	  from	  a	  chronically	  infected	  animal	  resulted	  in	  
variable	  TNFα	  and	  IFNβ	  production	  in	  response	  to	  SIVmac239	  Env	  peptide	  pools,	  
consistent	  with	  an	  ADCC	  response.	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Molecular Medicine graduate program at Johns Hopkins University and board certification in 
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Virion is a biotech company that primarily uses the cotton rat as an animal model for various 
human viral and bacterial diseases, including respiratory syncytial virus, herpes-2 virus, 
influenza, and tuberculosis.  
• Worked primarily with BSL-2 infectious agents 
• Designed and performed the herpes-2 virus animal studies 
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